Introduction {#s1}
============

RhoA activation during cytokinesis {#s1-1}
----------------------------------

Cell division involves the myosin-mediated contraction of an actin-based contractile ring. In metazoans, contractile ring assembly involves activation of the GTPase RhoA. RhoA directly activates formin-mediated actin polymerization and indirectly promotes myosin activation. As the contractile ring must assemble at the correct position and at the correct time, between the segregating chromosomes in anaphase, RhoA activation is subject to multiple regulatory mechanisms (see [@bib18] for review).

The primary direct activator of RhoA during cytokinesis is the RhoGEF ECT-2. ECT-2 contains N-terminal BRCT domains and a C-terminal RhoGEF domain ([@bib24]; [@bib53]). Presumably as a consequence of being autoinhibited, ECT-2 function depends on activators. One of the important activators of ECT-2 during cytokinesis is the centralspindlin complex, which is a heterotetramer containing a dimeric kinesin, ZEN-4 (aka MKLP1, Pavarotti) and dimeric CYK-4 (aka MgcRacGAP, Tum/RacGAP50C) ([@bib29]). Centralspindlin organizes the spindle midzone and directly recruits numerous regulators of cytokinesis, including ECT-2, to this location ([@bib3]; [@bib43]). ECT-2 and centralspindlin are conserved among---and restricted to---metazoans ([@bib14]) (unpublished results). Though these proteins are conserved, their names are distinct in each organism. For simplicity, *Caenorhabditis elegans* names will be used throughout this manuscript with the exception that we will refer to RHO-1 with the more common name RhoA.

Recruitment of ECT-2 to the spindle midzone involves regulated binding between ECT-2 and CYK-4. The BRCT domains of ECT-2 bind to CYK-4 phosphorylated by PLK-1 ([@bib3]; [@bib43]). CYK-4 phosphorylation occurs in a cell cycle and microtubule-regulated manner. Furthermore, CDK-1 phosphorylation of ECT-2 inhibits the ECT-2-CYK-4 interaction during metaphase and inactivates a membrane binding motif within ECT-2 ([@bib45]; [@bib36]). The phosphorylation-dependent interaction between ECT-2 and centralspindlin is required for RhoA activation during cytokinesis in human cells ([@bib4]; [@bib43]).

Centralspindlin also localizes in trace, but biologically relevant, amounts on the cell membrane. Centralspindlin accumulation to the midzone and the membrane are independently regulated by its oligomerization, which is inhibited by a 14-3-3 protein and promoted by the chromosome passenger complex ([@bib13]; [@bib1]).

The role of the GAP activity of CYK-4 GAP has been controversial {#s1-2}
----------------------------------------------------------------

The CYK-4 subunit of centralspindlin contains an evolutionarily conserved Rho family GTPase-activating protein (RhoGAP) domain ([@bib22]). The function of this domain has been examined in a number of different contexts. In vitro, the GAP domain of CYK-4 efficiently activates the GTPase activity of the Rho-family GTPases, CED-10/Rac1 and CDC-42. CYK-4 also has GAP activity towards RhoA, but it is far less active towards RhoA as compared to Rac1 and CDC-42 ([@bib40]; [@bib22]; [@bib2]). Despite extensive effort, there is no consensus for the biological role of this GAP activity (see [@bib42] for review). In some cell types, the GAP activity appears dispensable ([@bib17]; [@bib44]), in others it appears to be important to negatively regulate Rac1 ([@bib10]; [@bib7]; [@bib2]), whereas in yet others it appears to promote RhoA activation ([@bib10]; [@bib47]; [@bib27]). System-specific differences may underlie some of these diverse results. However, these studies differ in the mutations used to assess the function of the GAP domain, which is likely to affect the results. In addition, some of the controversy may be due to misinterpretation of indirect effects.

The function of the RhoGAP domain has been examined in *C. elegans* embryos in some detail. These studies have focused largely on a temperature-sensitive, separation-of-function substitution mutation, E448K, that lies in the RhoGAP domain of CYK-4, *cyk-4(or749ts)* ([@bib7]). The mutant protein can complex with the centralspindlin kinesin, ZEN-4, and bundle microtubules in the central spindle. However, cytokinesis does not proceed to completion in these embryos. Interestingly, depletion of CED-10/Rac1 or the actin nucleator subunit ARP-2 enables these embryos to complete cytokinesis ([@bib7]). These genetic interactions have been interpreted to indicate that the GAP domain of CYK-4 is important to keep CED-10/Rac1 inactive and prevent the accumulation of branched actin in the equatorial region ([@bib7]). However, subsequent analysis demonstrated that *cyk-4(or749ts)*; *ced-10(−)* embryos are phenotypically abnormal ([@bib27]). In particular, *cyk-4*; *ced-10* mutant embryos have reduced accumulation of RhoA effectors as compared to *ced-10* mutants alone ([@bib27]). These results suggest that this mutation in CYK-4 affects more than the RhoGAP activity of CYK-4 or that CED-10/Rac1 is not the relevant target of the GAP domain, or both.

Parallel mechanisms activate RhoA in the early *C. elegans* embryo {#s1-3}
------------------------------------------------------------------

Analysis of centralspindlin function in *C. elegans* embryos is impeded by the existence of a second, parallel pathway that promotes RhoA activation in the early embryo. Upon fertilization, embryos exhibit RhoA-dependent contractility that promotes embryo polarization and culminates in the formation of a transient furrow known as the pseudocleavage furrow. This wave of contractility requires a poorly conserved protein known as NOP-1 and is largely independent of centralspindlin ([@bib41]). Cytokinetic contractility, on the other hand, involves both NOP-1 and centralspindlin. However, *nop-1* is nonessential; loss of function mutants are viable and fertile ([@bib31]). Cytokinesis proceeds to completion in the absence of NOP-1, although furrow initiation is slightly delayed and RhoA accumulates to lower levels at the cleavage furrow ([@bib41]). Due to its role in RhoA activation, polarization in NOP-1-deficient embryos is also delayed. Mutational inactivation of NOP-1 permits direct analysis of centralspindlin-dependent furrow formation. Notably, when NOP-1 is inactivated, *cyk-4(or749ts)* embryos are completely defective in RhoA activation ([@bib41]).

Membrane-bound centralspindlin promotes RhoA activation {#s1-4}
-------------------------------------------------------

The CYK-4 GAP domain is adjacent to a C1 domain that mediates membrane localization of centralspindlin ([@bib26]). Given that the *cyk-4(or749ts)* substitution renders the protein thermosensitive, it is possible that these phenotypes are not the sole consequence of loss of GAP activity; this mutation could affect other functions of the GAP domain, the adjacent C1 domain may also be affected. To clarify these issues, we performed a targeted structure-function analysis of the C1 and GAP domains of CYK-4. We demonstrate that the *cyk-4(or749ts)* allele indeed affects its ability to associate with the membrane and show that this activity contributes to RhoA activation. We further show that the active site of the GAP domain contributes to the accumulation of downstream effectors of RhoA and RhoA-dependent contractility. Furthermore, we find that the catalytic domains of CYK-4 and ECT-2 directly interact in vitro. Finally, we show that hypomorphic defects in CYK-4-mediated RhoA dependent contractility can be suppressed by either loss of the RhoGAP activity provided by RGA-3/4 or by either of two activating mutations in ECT-2. These activating mutations in *ect-2* rescue *cyk-4(or749ts)* and GAP-deficient CYK-4. Our results indicate that CYK-4 GAP activity is involved in ECT-2-mediated RhoA activation.

Results {#s2}
=======

The *cyk-4(or749ts)* allele, E448K, exhibits defects in membrane association {#s2-1}
----------------------------------------------------------------------------

We sought to conduct a structure-function analysis of CYK-4 to determine the individual contributions of the GAP and C1 domains of CYK-4. We established a rescue assay based on single copy integrants of GFP-tagged CYK-4 transgenes driven by the *cyk-4* promoter inserted at a defined locus in the *C. elegans* genome using Mos1-mediated integration ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) ([@bib15]). The transgenes were expressed at consistent levels ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The transgenes were rendered resistant to an RNAi construct that could effectively deplete endogenous CYK-4 by targeting the 3′ UTR and portions of the coding sequence ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). By combining the appropriate mutant transgene with RNAi to specifically deplete endogenous CYK-4, we obtained embryos that express CYK-4^MUT^. In this and all subsequent experiments, when a given variant is assayed, endogenous CYK-4 is depleted by RNAi; these will be referred to as *cyk-4*^*mut*^ embryos. We first sought to validate the rescue assay, by assaying *cyk-4^E448K^* embryos and found that they closely phenocopy *cyk-4(or749ts)* embryos in which endogenous CYK-4 has the E448K substitution ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). This phenocopy indicates functional depletion of endogenous CYK-4. Additionally, a wild-type transgene was fully functional as it could complement a large deletion in CYK-4 to viability and fertility ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

Consistent with the C1 domain promoting membrane association, CYK-4^∆C1^ does not accumulate on ingressing cleavage furrows ([Figure 1A,B](#fig1){ref-type="fig"}). As *cyk-4(or749ts)* is temperature sensitive, we considered the possibility that the thermosensitivity also destabilizes the C1 domain that lies adjacent to the CYK-4 GAP domain ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Indeed, at the restrictive temperature, CYK-4^E448K^ exhibits a similar defect in localization as CYK-4^∆C1^ ([Figure 1A,B](#fig1){ref-type="fig"}). CYK-4 also associates with the membrane in the germline and indirect evidence suggests that this localization is compromised in embryos expressing CYK-4^E448K^ ([@bib51]). We generated strains in which both the endogenous *cyk-4* and the GFP-tagged transgene contained the E448K mutation. At the permissive temperature, CYK-4^E448K^ membrane recruitment was readily detected in the germline, however this localization was lost as animals were shifted to the restrictive temperature ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Similarly, the C1 domain is required for membrane localization in the gonad ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Thus, CYK-4^E448K^ impairs membrane localization, and it is likely to impair the function of both its GAP and C1 domains.10.7554/eLife.08898.003Figure 1.CYK-4-dependent membrane binding promotes furrow ingression.(**A**) CYK-4 accumulates on the plasma membrane. Membrane accumulation is observed on ingressing cleavage furrows (boxed regions). CYK-4 membrane accumulation requires the C1 domain and is compromised by the E448K substitution in the *cyk-4(or749ts)* allele. (**B**) Membrane accumulation of CYK-4 variants. The accumulation was quantified as a ratio of the accumulation of CYK-4::GFP/mCherry::PH at the furrow tip as depicted in the schematic; the mean intensity ±s.e.m. are plotted. (N = 8--12 embryos \*p \< 0.05, one way ANOVA followed by Tukey multiple comparison). (**C**) Deletion of the C1 domain and the E448K substitution impair cleavage furrow ingression. Kymographs generated from time-lapse recordings of the equatorial region of embryos of the indicated genotypes expressing the membrane marker mCherry::PH. Kymographs begin at anaphase onset. (**D**) Deletion of the C1 domain and the E448K substitution abrogate centralspindlin-dependent furrow ingression. The progression of cytokinesis was assessed in embryos expressing CYK-4 variants in combination with a loss of function mutation in *nop-1*. (**E**) Mutation of CED-10/Rac1 slightly increases furrow ingression in CYK-4^∆C1^ embryos and allows complete, albeit delayed, furrow ingression in CYK-4^E448K^ embryos. The progression of cytokinesis was assessed in embryos expressing CYK-4 variants in combination with a loss of function mutation in *ced-10*. (**F**--**I**) Quantification of furrow ingression rates in embryos of the indicated genotypes. Representative examples are shown in the accompanying kymographs. (N = 8--12 embryos; error bars, 95% confidence intervals). (**J**) The ability of *ced-10/Rac1* to rescue cytokinesis in CYK-4^E448K^ embryos requires the NOP-1 pathway for furrow ingression. Images shown reflect the maximal extent of furrow ingression in embryos of the indicated genotypes expressing the membrane marker mCherry::PH. Unless otherwise specified, all scale bars in all figures are 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.003](10.7554/eLife.08898.003)10.7554/eLife.08898.004Figure 1---figure supplement 1.CYK-4 structure, mutations, and methods of transgene integration.Schematic depiction of the domain organization of CYK-4, the variants tested, and the method for single copy transgene integration at a defined locus.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.004](10.7554/eLife.08898.004)10.7554/eLife.08898.005Figure 1---figure supplement 2.Transgene expression levels.(**A**) Quantification of the expression of CYK-4::GFP transgenes in embryos. Embryos were assayed in the first cell division and the total fluorescence intensity was measured. (N ≥ 8 embryos; error bars, s.e.m; \*\*\*p \< 0.001; n.s., not significant, by one way ANOVA followed by Tukey multiple comparison). (**B**) Quantification of the expression of CYK-4::GFP transgenes. Total worm lysates were prepared from adult worms, standardized for total protein concentration and blotted with an anti-CYK-4 antibody. In the case of the RNAi experiment, 120 gravid adults worms were treated with *cyk-4(RNAi)* or control treated and subjected to western blotting.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.005](10.7554/eLife.08898.005)10.7554/eLife.08898.006Figure 1---figure supplement 3.The CYK-4^E448K^::GFP transgene combined with *cyk-4(RNAi)* closely phenocopies *cyk-4(or749ts)*.Quantification of furrow ingression rates in embryos of the indicated genotypes. Results are quantified as described in [Figure 1G](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.006](10.7554/eLife.08898.006)10.7554/eLife.08898.007Figure 1---figure supplement 4.Assay for localization of CYK-4 variants to the membrane of the gonad.(**A**) CYK-4^E448K^ exhibits temperature sensitive binding to the incomplete membranes of the syncytial hermaphrodite gonad. Animals in which both endogenous and the GFP-tagged transgene contain the E448K substitution were imaged either immediately after removal from a 16°C incubator or after 60 min at 25°C. At the permissive temperature, CYK-4^E448K^ binds to the gonad membrane, but not at the restrictive temperature. (**B**) The localization of CYK-4^WT^, CYK-4^∆C1^, and CYK-4^R459A^ was analyzed in hermaphrodite gonads. mCherry::PH was used to mark the membranes in the syncytial gonad. Whereas both CYK-4^WT^ and CYK-4^R459A^ label the membranes in the syncytial gonad, CYK-4^∆C1^ does not.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.007](10.7554/eLife.08898.007)

We compared the progression of cytokinesis in embryos expressing CYK-4^WT^, CYK-4^∆C1^, and CYK-4^E448K^. CYK-4^∆C1^ embryos exhibit a cytokinetic defect that is largely similar to that of *cyk-4^E448K^* embryos*.* In particular, furrow ingression is slow and incomplete ([Figure 1C,F](#fig1){ref-type="fig"}). However, subtle differences were detected; the onset of significant furrow ingression is delayed relative to controls in *cyk-4^E448K^* embryos but not in *cyk-4*^*∆C1*^ embryos. This suggests that the CYK-4^E448K^ phenotype could reflect a compound defect, rather than a sole defect in the ability to associate with the membrane.

Cleavage furrow ingression in *C. elegans* depends on the combined action of centralspindlin and a non-essential protein, NOP-1 ([@bib41]). To determine whether the C1 domain is essential for centralspindlin-dependent furrow ingression, we expressed CYK-4^WT^, CYK-4^∆C1^, and CYK-4^E448K^ in embryos that lack the NOP-1-dependent pathway for furrow ingression. As expected, CYK-4^WT^ supports full furrow ingression in this sensitized background. In stark contrast, neither CYK-4^∆C1^ nor CYK-4^E448K^ support detectable furrow ingression in the absence of NOP-1 activity ([Figure 1D,G](#fig1){ref-type="fig"}).

Previous studies demonstrated that loss of function mutations in *ced-10/rac-1* or depletion of the protein partially suppress the cytokinesis defect in *cyk-4(or749ts)* embryos ([Figure 1E,H](#fig1){ref-type="fig"}). However, as described above, it is important to examine the extent of suppression in the absence of the parallel, NOP-1-dependent, pathway. We therefore examined whether *ced-10/rac-1* loss of function mutations could suppress the cytokinesis defect in *cyk-4*^*∆C1*^. Although cleavage furrows in *cyk-4*^*∆C1*^; *ced-10(n1993)* embryos ingress somewhat more deeply than *cyk-4*^*∆C1*^ embryos, they do not complete cytokinesis ([Figure 1E,H](#fig1){ref-type="fig"}). The simplest interpretation of these results is that although CYK-4^E448K^ diminishes membrane association of CYK-4, it may retain some function at the restrictive temperature such that it facilitates the abscission step in *cyk-4(or749ts); ced-10(n1993)* embryos, as CYK-4-mediated membrane association is essential for completion of cytokinesis in cultured human cells ([@bib26]). Importantly, when NOP-1 activity is compromised, inactivation of CED-10/Rac1 does not suppress the defect in furrow ingression caused by CYK-4^E448K^ ([Figure 1J,I](#fig1){ref-type="fig"}), suggesting that CYK-4 does not act directly on CED-10.

Mutants in the active site of the CYK-4 GAP domain are cytokinesis-defective {#s2-2}
----------------------------------------------------------------------------

To begin to determine the role of the catalytic activity of CYK-4 during cytokinesis, we first studied the consequence of mutating the highly conserved catalytic arginine that stabilizes the transition state during GTP hydrolysis. Substitution of the catalytic arginine with alanine strongly attenuates GAP activity against Rac in a variety of CYK-4 orthologs and is widely used to inactivate Rho family GAPs ([@bib30]; [@bib44]; [@bib28]; [@bib2]; [@bib46]). As expected, CYK-4^R459A^ GAP domain retains the ability to bind to RhoA•GTP, demonstrating that the protein is well folded in vitro ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). While CYK-4 GAP exhibits GAP activity towards both RhoA and CED-10/Rac1, CYK-4^R459A^ GAP lacks detectable GAP activity towards either GTPase ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). In order to determine if catalytic activity is required for viability, we used a strain heterozygous for a deletion mutant of CYK-4, *cyk-4(ok1034)*. One quarter of the embryos from these heterozygous hermaphrodites contain maternally provided CYK-4 and lack zygotic CYK-4. These zygotic null embryos fail to hatch and arrest with a variety of terminal phenotypes ([Figure 2A](#fig2){ref-type="fig"}, left). Many, but not all, embryos contain muscle tissue and have undergone partial morphogenesis. The embryos also contain enlarged cells, likely due to defects in cytokinesis ([@bib37]). We introduced the GAP-defective transgene into this strain. Remarkably, *cyk-4(ok1034)*; *cyk-4^R459A^* animals hatch and develop to adulthood. However, these animals are sterile ([Figure 2A](#fig2){ref-type="fig"}, middle). Thus, the GAP activity of CYK-4 is not essential for post embryonic development but it has an important role in gonad development, likely due to a requirement for post-embryonic cell proliferation in the germline. As a consequence, it is not possible to use classical genetic tools to obtain embryos in which CYK-4^R459A^ is the sole form of CYK-4.10.7554/eLife.08898.008Figure 2.CYK-4 GAP activity is required for cytokinesis and viability.(**A**) *cyk-4(ok1034)* null embryos arrest at variable stages during embryogenesis (left). The GAP-deficient CYK-4^R459A^ transgene rescues the embryonic lethality, but animals arrest as sterile adults (middle). GAP-deficient CYK-4^R459A^ is recessive, no phenotypes is seen in the presence of *cyk-4(+)* (right). Right scale bar 50 µm. (**B**) GAP-deficient CYK-4^R459A^ embryos fail to complete cytokinesis. Kymographs are generated as in [Figure 1D](#fig1){ref-type="fig"}, with the exception that the signal from the CYK-4 transgenes is also shown (green), overlaid on mCherry::PH (red). CYK-4^R459A^ accumulates more strongly at furrow tips as compared to CYK-4^WT^ (arrows). (**C**) The kinetics of furrow ingression in CYK-4^WT^ and CYK-4^R459A^ embryos. Results are quantified as described in [Figure 1G](#fig1){ref-type="fig"}. (**D**) Membrane accumulation of CYK-4^WT^ and CYK-4^R459A^. Results are quantified as described in [Figure 1B](#fig1){ref-type="fig"} (\*\*p \< 0.01, by t-test).**DOI:** [http://dx.doi.org/10.7554/eLife.08898.008](10.7554/eLife.08898.008)10.7554/eLife.08898.009Figure 2---figure supplement 1.Binding of CYK-4 variants to RhoA.(**A**) Schematic of the domain structure of full length CYK-4 and the recombinant GAP domains used in binding studies. The positions of the relevant mutations are indicated. (**B**) Binding assays between CYK-4 C1GAP domains and GST-tagged RhoA complexed with GTPγS. CYK-4^WT^ GAP domain binds to RhoA•GTPγS. The CYK-4^EE^ GAP domain exhibits reduced binding to RhoA•GTPγS, whereas CYK-4^R459A^ GAP domain exhibits increased binding to RhoA•GTPγS. (**C**) GST-pulldown assays between GST-RhoA•GTPγS and CYK-4 GAP/C domain variants. Wild-type CYK-4 GAP binds to RhoA•GTPγS. CYK-4^R459A^ GAP exhibits increased binding to RhoA•GTPγS, whereas CYK-4^EE^ GAP exhibits reduced binding to RhoA•GTPγS. None of the CYK-4 GAP variants exhibit binding activity to GST alone. (**D**) Proteins used in binding assays in (**C**).**DOI:** [http://dx.doi.org/10.7554/eLife.08898.009](10.7554/eLife.08898.009)10.7554/eLife.08898.010Figure 2---figure supplement 2.GAP activity of CYK-4 and variants.(**A**) Time course of GTP hydrolysis by RhoA in the presence or absence of 200 nM CYK-4 GAP or CYK-4^R459A^ GAP. (**B**) Titration of CYK-4 GAP activity towards CED-10/Rac1 and RhoA. Free phosphate was measured after 30 min.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.010](10.7554/eLife.08898.010)

To study the role of the CYK-4 GAP activity during embryogenesis, we used the aforementioned assay ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Embryos, expressing only CYK-4^R459A^, are largely normal during the initial stages of the first cell cycle. They undergo pseudocleavage, mitotic spindle assembly, chromosome segregation, central spindle assembly during anaphase, and CYK-4^R459A^ becomes highly enriched on the spindle midzone ([Figure 2B](#fig2){ref-type="fig"}). Cleavage furrow initiation occurs and the furrow ingresses at near wild-type rates to near completion. However, cytokinesis does not complete and the furrow ultimately regresses; this phenotype was fully penetrant ([Figure 2C](#fig2){ref-type="fig"}); these embryos also fail to complete cytokinesis following meiosis II (data not shown). These results suggest that a late step in cytokinesis is most sensitive to loss of CYK-4 GAP activity. This phenotype is distinct from that of *cyk-4(or749ts)* embryos--cleavage furrows in *cyk-4^R459A^* embryos ingress more rapidly and more deeply than *cyk-4^E448K^* embryos ([Figure 1C](#fig1){ref-type="fig"}). We assessed the ability of CYK-4^R459A^ to associate with membrane during furrow ingression ([Figure 2B,D](#fig2){ref-type="fig"}). CYK-4^R459A^ hyper accumulates on the membrane as compared to WT CYK-4; this localization suggests that CYK-4R459A is well folded in vivo. Therefore, the cytokinetic defect in this strain is unlikely to be an indirect consequence of a failure of CYK-4 to localize to the membrane.

CYK-4 GAP domain mutations that prevent RhoA binding are highly defective in RhoA activation {#s2-3}
--------------------------------------------------------------------------------------------

To extend these results, confirm that CYK-4 must interact with Rho family GTPases during cytokinesis, and eliminate the possibility that the phenotype of CYK-4^R459A^ is due to enhanced binding of CYK-4 to active RhoA, we engineered mutations in CYK-4 that reduce its binding to RhoA and other GTPases ([@bib30]; [@bib34]). Two conserved, surface exposed, basic residues in the RhoA interface (K495, R499) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) were charge reversed to glutamic acid, generating CYK-4^EE^, and characterized in the transgenic rescue assay. Embryos expressing only CYK-4^EE^, like those expressing CYK-4^R459A^ and CYK-4^∆C1^, exhibit fully penetrant embryonic lethality ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). CYK-4^EE^ exhibits reduced binding to RhoA in vitro ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), and it does not exhibit membrane hyperaccumulation in vivo ([Figure 3A,B](#fig3){ref-type="fig"}). Interestingly, *cyk-4*^*EE*^ embryos exhibit a stronger furrow ingression defect than *cyk-4^R459A^* embryos, as furrow ingression is slower and less complete ([Figure 3C,D](#fig3){ref-type="fig"}). Importantly, NOP-1 depletion from *cyk-4*^*EE*^ embryos largely eliminates furrow ingression ([Figure 3C,D](#fig3){ref-type="fig"}). Thus, Rho GTPase binding by CYK-4 is essential for centralspindlin-mediated cytokinetic ingression.10.7554/eLife.08898.011Figure 3.RhoA binding by CYK-4 is required for cytokinesis.(**A**) CYK-4^R459A^, but not CYK-4^EE^, hyperaccumulates on the plasma membrane of the ingressing cleavage furrows (boxed regions). (**B**) Membrane accumulation of CYK-4::GFP variants was quantified as described in [Figure 1B](#fig1){ref-type="fig"}. (N = 8--12 embryos; \*\*p \< 0.01, by one way ANOVA followed by Tukey multiple comparison). (**C**) The Rho family GTPase binding defective variant of CYK-4, CYK-4^EE~,~^ , causes cytokinesis defects. Kymograph analysis of the progression of cytokinesis in CYK-4^EE^ embryos in the presence or absence of NOP-1 function. Kymographs were assembled as described in legend to [Figure 1D](#fig1){ref-type="fig"}. (**D**) The kinetics of furrow ingression in CYK-4^EE^ embryos. Results are quantified as described in [Figure 1G](#fig1){ref-type="fig"}. (**E**) Inactivation of CDC-42 and CED-10/Rac1, either alone or in combination, does not cause cytokinesis defects in the sensitized *nop-1* background. Kymographs were assembled as described in legend to [Figure 1D](#fig1){ref-type="fig"}. Note that depletion of CDC-42 results in symmetric cleavage furrow ingression. (**F**) The kinetics of furrow ingression in embryos deficient in *nop-1* and/or CDC-42 and/or CED-10/Rac1 function. Results are quantified as described in [Figure 1G](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.011](10.7554/eLife.08898.011)10.7554/eLife.08898.012Figure 3---figure supplement 1.Location and conservation of mutated residues in the CYK-4 GAP domain.(**A**) Alignment of a region of the GAP domain of CYK-4 from various species and the unrelated RhoGAP P50. The positions of the catalytic arginine (Ce 459) and the conserved basic residues (Ce K495/R499) are indicated. Accession numbers Q9H0H5.1; Q9WVM1.1; AAF58324.1; CAB04593.1; Q07960.1. (**B**) Embryonic lethality of CYK-4 variants at two temperatures. *cyk-4*^*R459A*^*::gfp*, *cyk-4*^*EE*^*::gfp*, and *cyk-4*^*∆C1*^*::gfp* exhibit fully penetrant embryonic lethality at 16°C and 25°C. *cyk-4*^*WT*^*::gfp* is included as a control.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.012](10.7554/eLife.08898.012)

We next sought to determine the Rho family GTPase to which CYK-4 must bind to fulfill its function in vivo. If furrow formation is dependent on CYK-4 binding to either CED-10/Rac1 or CDC-42 to generate a positive regulatory complex, then inactivation of these GTPases would be predicted to cause a phenotype at least as severe as a mutation that weakens the GTPase binding site of CYK-4. However, mutation of CED-10/Rac1, or depletion of CDC-42, does not affect the rate of cleavage furrow ingression ([@bib22]; [@bib27]), even when combined with mutations in NOP-1 ([Figure 3E,F](#fig3){ref-type="fig"}). Indeed, cytokinesis occurs efficiently and proceeds to completion in embryos in which NOP-1, CED-10/Rac1, and CDC-42 are simultaneously inactivated ([Figure 3E,F](#fig3){ref-type="fig"}). We infer, therefore, that RhoA is the relevant GTPase that CYK-4 binds to promote cleavage furrow formation. Due to its direct role in furrow ingression, it is not possible to test RhoA in the same manner.

CYK-4 GAP domain mutations are defective in centralspindlin-dependent furrowing {#s2-4}
-------------------------------------------------------------------------------

We next sought to determine how the GAP activity of CYK-4 promotes cytokinesis. Previous studies proposed at least three models for the phenotype seen in *cyk-4^R459A^* embryos. First, the GAP domain could function as canonical GAP that acts on RhoA, causing CYK-4 GAP-deficient embryos fail to complete cytokinesis because of a requirement for RhoA inactivation at late cytokinesis. Second, CED-10/Rac1 could be an important target of CYK-4 GAP activity, causing CYK-4 GAP deficient embryos to accumulate ectopic Rac1 activity that interferes with cytokinesis. Third, although it is counterintuitive, CYK-4 GAP activity could somehow promote RhoA activation, and therefore the CYK-4 GAP deficient embryos may fail cytokinesis due to incomplete RhoA activation. We sought to distinguish between these alternatives.

The first and third models make opposite predictions for the outcome of experiments in which RhoA levels are perturbed ([Figure 4A](#fig4){ref-type="fig"}). If the failure to complete cytokinesis in *cyk-4^R459A^* embryos is due to hyperactivation of RhoA, as would be predicted from the canonical model for the function of a RhoA GAP, then a reduction in active RhoA levels might ameliorate the defect. Conversely, if the GAP active site promotes RhoA activation, then the reduction of RhoA activity would be predicted to exacerbate the phenotype of *cyk-4^R459A^*. To distinguish between these models, we reduced RhoA levels by mutationally inactivating NOP-1. As expected, all control embryos (*nop-1(it142)*; *cyk-4*^WT^) complete cytokinesis ([Figure 4Bi](#fig4){ref-type="fig"}). Surprisingly, *nop-1(it142); cyk-4^R459A^* mutant embryos exhibit extremely weak furrow ingression; furrows in these embryos ingressed less than ∼10% of egg width ([Figure 4Biii,C](#fig4){ref-type="fig"}). This result supports models in which CYK-4 GAP activity is involved in RhoA activation.10.7554/eLife.08898.013Figure 4.The GAP activity of CYK-4 is required for centralspindlin-dependent furrowing independent of CED-10/Rac1.(**A**) Schematic depiction of the known regulators of RhoA. (**B**) GAP defective CYK-4 causes cytokinesis defects that are greatly enhanced by loss of NOP-1 function; this defect is not fully suppressed by mutation of *ced-10/rac1*. Kymograph analysis of the progression of cytokinesis in CYK-4^R459A^ embryos in the presence or absence of CED-10/Rac1 and/or NOP-1 function. The kinetics of furrow ingression in *cyk-4*^*WT*^*::gfp; nop-1(it142)* and *nop-1(it142); ced-10(n1993)* embryos are shown for comparison. Kymographs were assembled as described in legend to [Figure 1D](#fig1){ref-type="fig"}. (**C**) The kinetics of furrow ingression in CYK-4^R459A^ embryos. Results are quantified as described in [Figure 1G](#fig1){ref-type="fig"}. The kinetics of furrow ingression in *cyk-4*^*WT*^*::gfp; nop-1(it142)* and *nop-1(it142); ced-10(n1993)* embryos from [Figures 1F, 3F](#fig1 fig3){ref-type="fig"} are shown as dashed lines for comparison.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.013](10.7554/eLife.08898.013)10.7554/eLife.08898.014Figure 4---figure supplement 1.Depletion of ARX-2, but not RAC-2, suppresses the cytokinesis defect in CYK-4^R459A^ embryos.The kinetics of furrow ingression in CYK-4^R459A^ embryos depleted of RAC-2 or ARX-2. Results are quantified as described in [Figure 1G](#fig1){ref-type="fig"}. The kinetics of furrow ingression in *cyk-4^R459A^::gfp* embryos from [Figure 4D](#fig4){ref-type="fig"} is shown for comparison.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.014](10.7554/eLife.08898.014)10.7554/eLife.08898.015Figure 4---figure supplement 2.A gain of function mutation, *mig-2(gm103)*, does not affect cytokinesis in sensitized backgrounds.NOP-1 or ZYG-9 was depleted from *mig-2(gm103)* embryos and the progression of cytokinesis was followed by nomarski imaging. Cytokinesis proceeds to completion in the former case, and both anterior (left) and posterior (right) furrows are formed in the latter case. ZYG-9 was depleted from *cyk-4^R459A^::gfp* embryos for comparison demonstrating loss of the posterior furrow.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.015](10.7554/eLife.08898.015)10.7554/eLife.08898.016Figure 4---figure supplement 3.Depletion of neither ARX-2 nor RAC-2 modulates the cytokinesis defect in *nop-1; ced-10; cyk-4^R459A^* embryos.The kinetics of furrow ingression in *cyk-4^R459A^::gfp*; *nop-1(it142); ced-10(n1993)* embryos depleted of either ARX-2 or RAC-2. Results are quantified as described in [Figure 1G](#fig1){ref-type="fig"}. The kinetics of furrow ingression in *nop-1(it142); cyk-4*^*WT*^*::gfp*, *cyk-4^R459A^::gfp*; *nop-1(it142), and cyk-4^R459A^::gfp*; *nop-1(it142); ced-10(n1993)* embryos from [Figures 1G, 4C](#fig1 fig4){ref-type="fig"} are shown for comparison.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.016](10.7554/eLife.08898.016)

*ced-10(−)* only partially bypasses loss of CYK-4 GAP activity {#s2-5}
--------------------------------------------------------------

Previous studies have implicated CED-10/Rac1 as a target of CYK-4 GAP activity, although these studies utilized the *cyk-4(or749ts)* mutation that impairs membrane localization of CYK-4 ([Figure 1A,B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}). Therefore, we addressed whether loss of function mutations in *ced-10* affect cytokinesis in *cyk-4^R459A^* embryos. Interestingly, we found that all *ced-10;* *cyk-4^R459A^* embryos fully ingress and 75% complete cytokinesis ([Figure 4Biv,C](#fig4){ref-type="fig"}), suggesting significant, albeit incomplete rescue. Depletion of ARX-2, a component of the Arp2/3 complex, a downsteam effector of Rac GTPases, provides similar rescue as mutation in *ced-10* ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"})*.* Two other Rac related proteins, RAC-2 and MIG-2, could, in principle, be additional targets of the CYK-4 GAP domain. However, depletion of RAC-2 does not rescue completion of cytokinesis in *cyk-4^R459A^* embryos ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Furthermore, gain of function mutations in *mig-2* ([@bib52]) do not cause cytokinesis defects, even in sensitized genetic backgrounds ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

Mutations in *ced-10* also slightly increase the extent of furrow ingression in *cyk-4*^*∆C1*^ embryos ([Figure 1E,H](#fig1){ref-type="fig"}). To more stringently test whether the GAP activity of CYK-4 is linked with CED-10/Rac1 inactivation, we assessed the progression of cytokinesis in embryos that lack NOP-1 function. Crucially, *nop-1*; *ced-10* embryos complete cytokinesis ([Figure 4Bvi](#fig4){ref-type="fig"}). If CED-10/Rac1 inactivation is the primary function of the CYK-4 GAP domain, then CYK-4 GAP activity would be predicted to be dispensable in *nop-1*; *ced-10* embryos. However, in stark contrast to this prediction, *nop-1*; *ced-10*; *cyk-4^R459A^* embryos fail to form ingressing cleavage furrows altogether ([Figure 4Bv,C](#fig4){ref-type="fig"}). Significant furrow ingression is not restored by depletion of either RAC-2 or ARX-2 in *nop-1*; *ced-10*; *cyk-4^R459A^* embryos, suggesting that the cytokinesis defect is not due to activation of other Rac-family proteins ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). These data demonstrate that the catalytic activity of the CYK-4 GAP domain must have a function that is distinct from maintaining CED-10/Rac1 in an inactive state.

Mutations in the active site of CYK-4 can be suppressed by RGA-3/4 depletion {#s2-6}
----------------------------------------------------------------------------

To further test models in which CYK-4 RhoGAP catalytic activity is important to either promote RhoA activation or to promote RhoA inactivation, we examined the consequence of depletion of the predominant RhoA GAP in the early embryo, RGA-3/4 ([@bib32]; [@bib33]). As previously shown, depletion of RGA-3/4 causes cortical hypercontractility in otherwise wild-type embryos, during both pseudocleavage and cytokinesis, and results in embryonic lethality ([Figure 5A](#fig5){ref-type="fig"}) ([@bib32]; [@bib33]). When RGA-3/4 is depleted from *cyk-4^R459A^* embryos, all embryos complete cytokinesis ([Figure 5B](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}), further suggesting that the GAP activity of CYK-4 promotes, rather than counteracts, RhoA activation.10.7554/eLife.08898.017Figure 5.Depletion of RGA-3/4 rescues cytokinesis in CYK-4^R459A^ embryos.(**A**) Schematic depiction of the known regulators of RhoA. (**B**) Representative embryos demonstrating the effect of RGA-3/4 depletion on cytokinesis in CYK-4^R459A^ embryos both in the presence and absence of NOP-1 function. (**C**) Depletion of RGA-3/4 rescues cytokinesis specifically in CYK-4^R459A^ embryos. CYK-4^∆C1^, CYK-4^EE^, CYK-4^R459A^ where expressed in *nop-1(it142)* embryos and the extent of furrow closure measured either in the presence (green) or the absence (red) of RGA-3/4. (**D**) Accumulation of the RhoA effector NMY-2 (tagged with RFP) in embryos of the indicated genotypes. Embryos are shown at ∼50% (or maximal) ingression. Note the reduction of cortical myosin accumulation in CYK-4^R459A^, CYK-4^EE^, CYK-4^∆C1^ embryos as compared to CYK-4^WT^ (i--iv). The severity of this reduction is enhanced by inactivation of NOP-1 (i′--iv′). Depletion of RGA-3/4 restores myosin accumulation in CYK-4^R459A^ and CYK-4^EE^ embryos (v, vi), even in embryos defective in NOP-1 function (v′, vi′). (**E**) Quantification of total NMY-2::mRFP accumulation in the furrow region over the course of cytokinesis in embryos of the indicated genotypes. Error bars, s.e.m.; n.s. (not significant); \#p \< 0.05; \#\#\#p \< 0.001 refers to significance relative to wild-type in *nop-1(+)* and *nop-1(it142),* respectively by one way ANOVA followed by Tukey multiple comparison. \*\*\*p \< 0.001 for the indicated comparison.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.017](10.7554/eLife.08898.017)10.7554/eLife.08898.018Figure 5---figure supplement 1.Furrow ingression of RGA-3/4-depleted embryos expressing CYK-4 variants.(**A**) Line graphs depicting the kinetics of furrow ingression in (**A**) \[*cyk-4(RNAi)*, CYK-4^∆C1^, CYK-4^EE^, CYK-4^R459A^\]; *nop-1(it142); rga-3/4(RNAi)* embryos and (**B**) \[*cyk-4(RNAi)*, CYK-4^EE^, CYK-4^R459A^\]; *rga-3/4(RNAi)*. These data are summarized in [Figure 5C](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.018](10.7554/eLife.08898.018)10.7554/eLife.08898.019Figure 5---figure supplement 2.Comparison between accumulation of NMY-2::RFP and the RhoA biosensor during cytokinesis.(**A**) Correlation between the accumulation of NMY-2::mRFP and GFP::AHPH (RhoA biosensor \[[@bib41]\]) in embryos of the indicated genotypes. Each spot corresponds to the average integrated intensity of the saturation \> signal \>1.5\*cytoplasmic background in a pair of images during cytokinesis (i.e., each embryo is represented by 9--11 dots). The data are fit to a line as shown. (**B**) Gallery of images showing the distribution of NMY-2::mRFP and GFP::AHPH in the furrow region during cytokinesis in sets of embryos of the indicated genotypes.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.019](10.7554/eLife.08898.019)

To test this model more stringently, we asked whether cytokinesis also completes when RGA-3/4 is depleted from *cyk-4^R459A^* embryos also lacking NOP-1 (i.e., *nop-1(it142)*; *rga-3/4(RNAi)*; *cyk-4^R459A^* embryos). Remarkably, although furrows in *cyk-4^R459A^; nop-1* embryos barely ingress, when RGA-3/4 is depleted, furrow ingression is completed in 100% of embryos ([Figure 5B,C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). This result also rules out the possibility that RGA-3/4 depletion allows completion of cytokinesis because it stabilizes RhoA that was activated in a NOP-1-dependent manner. Depletion of RGA-3/4 did not significantly modify the cytokinetic phenotype of *nop-1; cyk-4(RNAi)* embryos ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), demonstrating CYK-4 dependence to this suppression. Furthermore, complete suppression was specific to *cyk-4^R459A^* embryos, depletion of RGA-3/4 induced deeper but still incomplete ingression in *nop-1; cyk-4*^*EE*^ and *nop-1; cyk-4*^*∆C1*^ embryos. These strains formed an allelic series in order of decreasing extents of ingression: *cyk-4^R459A^* \> *cyk-4*^*EE*^ \> *cyk-4*^*∆C1*^ ∼ *cyk-4(RNAi)* ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}).

Mutations in the GAP domain of CYK-4 prevent accumulation of RhoA effectors {#s2-7}
---------------------------------------------------------------------------

RhoA is a dose dependent regulator of cleavage furrow formation ([@bib27]) and CYK-4 is involved in RhoA activation by relieving autoinhibition of ECT-2 ([@bib24]; [@bib45]). We therefore assayed whether CYK-4 GAP domain mutations affect accumulation of RhoA effectors. Because the RhoA biosensor and the CYK-4 transgenes are both GFP-tagged and integrated at the same position of the genome, we assayed the accumulation of RFP-tagged non-muscle myosin, NMY-2, a key effector of RhoA, as a proxy for RhoA activation. To validate that NMY-2::mRFP is a valid proxy for RhoA activity levels, we compared the accumulation of these two markers to the cleavage furrow during cytokinesis when co-expressed. The recruitment of NMY-2::mRFP and the RhoA biosensor are highly correlated in space, time, and intensity ([Figure 5---figure supplement 2A,B](#fig5s2){ref-type="fig"}). In addition, the correlation between these markers remains strong when either NOP-1, CYK-4, or RGA-3/4 are depleted, despite the significant changes in the extent of recruitment caused by these perturbations. Thus NMY-2::mRFP provides a reliable proxy for RhoA activation.

We assayed NMY-2::mRFP levels in CYK-4^WT^, CYK-4^∆C1^, CYK-4^R459A^, and CYK-4^EE^ embryos during anaphase. Mutations in CYK-4 that reduce the rate and extent of cleavage furrow also reduce NMY-2::mRFP accumulation ([Figure 5D](#fig5){ref-type="fig"}, top row, [Figure 5E](#fig5){ref-type="fig"}). The defect in myosin accumulation caused by mutations in the GAP domain of CYK-4 is far more severe and apparent in NOP-1-depleted embryos ([Figure 5D](#fig5){ref-type="fig"}, bottom row, [Figure 5E](#fig5){ref-type="fig"}). Conversely, depletion of RGA-3/4 increases myosin accumulation in CYK-4^R459A^ and CYK-4^EE^ embryos, both in the presence and absence of NOP-1. These data support models in which the catalytic activity of the CYK-4 GAP domain contributes to RhoA activation.

CYK-4 GAP domain mutations can be suppressed by gain of function mutations in *ect-2* {#s2-8}
-------------------------------------------------------------------------------------

To obtain additional insight into the mechanism by which CYK-4 promotes cytokinesis, we took an unbiased genetic suppression approach. We mutagenized *cyk-4(or749ts)* animals, grew the mutagenized animals at the permissive temperature for two generations to allow potential suppressors to become homozygous and shifted them to 25°C to select for suppressors. We isolated three strong suppressors out of a total of ∼10\^5 mutagenized F1 genomes. Suppressor strains were subjected to sequencing of the *cyk-4* locus to identify potential intragenic suppressors. One strain contained a substitution mutation in CYK-4, H485Y, relatively close to the *or749ts* substitution E448K ([Figure 6A](#fig6){ref-type="fig"}). We also isolated two strong extragenic suppressors, *xs110* and *xs111,* that rescue *cyk-4(or749ts)* to viability at the restrictive temperature. The suppressed strains complete cytokinesis with high efficiency (\>90%) and support high viability ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).10.7554/eLife.08898.020Figure 6.Mutations in ECT-2 suppress *cyk-4(or749ts)*.(**A**) Schematic depicting the domain structure of CYK-4 and ECT-2 with the positions of the mutations isolated in the *cyk-4(or749ts)* suppressor screen. (**B**) *ect-2(xs110)* and *ect-2(xs111)* suppresses both *cyk-4(or749ts)* and CYK-4^R459A^. Images of embryos of the indicated genotypes are shown at the pronuclear stage and during cytokinesis. Both *ect-2(xs110)* (i) and *ect-2(xs111)* (v) embryos exhibit hypercontractility (arrows) that is suppressed by *cyk-4(or749ts)* (ii and vii). Depletion of NOP-1 from *cyk-4(or749ts)*; *ect-2(xs110)* eliminates contractility during pseudocleavage and greatly reduces contractility during cytokinesis (iii). Depletion of NOP-1 from *cyk-4(or749ts)*; *ect-2(xs111)* eliminates contractility during pseudocleavage but cytokinesis is still observed (viii). e*ct-2(xs110)* and *ect-2(xs111)* both allow cytokinetic completion in CYK-4^R459A^ (iv, ix). Depletion of CYK-4 prevents completion of cytokinesis in *ect-2(xs110)* and *ect-2(xs111) (v, x)*. Phenotypes shown were seen in (i) 18/18 embryos; (ii) 11/12; (iii) 7/16, 5/16 showed less contractility; (iv) 6/6; (v) 7/7; (vi) 14/14; (vii) 18/18; (viii)13/16; (ix) 6/6; (x) 6/6. (**C**) *ect-2(xs110)* and *ect-2(xs111)* suppress *cyk-4(or749ts)*. The kinetics of furrow ingression in *cyk-4(or749ts)* embryos and in the suppressed strains. Results are quantified as described in [Figure 1G](#fig1){ref-type="fig"}. (**D**) *ect-2(xs110)* causes defects in cleavage plane positioning. The position of furrow initiation and the spindle midzone are indicated in yellow and purple, respectively (see schematic). (**E**) Quantification of the mean position of the central spindle (±s.e.m) as a function of egg length in wild-type and *ect-2(xs110)* embryos. (**F**) Quantification of the mean position of furrow initiation (±s.e.m) relative to the center of the spindle midzone in wild-type and *ect-2(xs110)* embryos. (\*\*\*p \< 0.001, by t-test).**DOI:** [http://dx.doi.org/10.7554/eLife.08898.020](10.7554/eLife.08898.020)10.7554/eLife.08898.021Figure 6---figure supplement 1.Viability and fertility of *cyk-4* mutants and suppressors.Mean brood size and hatch rates of strains of the indicated genotypes (n/t, not tested). All strains were tested at 25°C.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.021](10.7554/eLife.08898.021)10.7554/eLife.08898.022Figure 6---figure supplement 2.Conservation of ECT-2 GEF domain and inferred position of the *ect-2(xs110)* allele.(**A**) Sequence alignment of DHPH domains from ECT-2 orthologs and other GEFs highlighting the position of the G707. Accession numbers: Q9H8V3.4; AAF50508.2; O15085.1; Q92888.2; CAB54311.1; Q64096.2. (**B**) Portion of the crystal structure (1XCG) of PDZRhoGEF (green, DH domain; red, PH domain; blue, RhoA). The equivalent to G707, N1068 is highlighted.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.022](10.7554/eLife.08898.022)10.7554/eLife.08898.023Figure 6---figure supplement 3.Accumulation of myosin during cytokinesis in *ect-2(xs110)*.*ect-2(xs110)* results in hyperaccumulation of NMY-2::GFP during cytokinesis.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.023](10.7554/eLife.08898.023)10.7554/eLife.08898.024Figure 6---figure supplement 4.*ect-2(xs110)* and *ect-2(xs111)* are dominant gain of function mutations.Nomarski imaging of *ect-2(xs110)/+ and ect-2(xs111)/+* during pseudocleavage and cytokinesis. Hypercontractility (arrows) is observed in the presence of a wild-type allele of *ect-2*.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.024](10.7554/eLife.08898.024)

Candidate extragenic suppressors were genetically mapped to chromosome II near the *ect-2* locus. Substitution mutations in the *ect-2* locus were identified in both suppressor strains ([Figure 6A](#fig6){ref-type="fig"}). *ect-2(xs110)* contained a single nucleotide change in the PH domain, resulting in a G707D substitution ([Figure 6A](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). In a related RhoGEF for which there is a co-crystal structure with RhoA (PDZRhoGEF), the residue analogous to G707 lies in an α helix in the PH domain that comes into close proximity to the α3 helix of RhoA ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}) ([@bib9]).

We recorded the progression of cytokinesis in *cyk-4(or749ts); ect-2(xs110)* embryos and found that the embryos not only complete cytokinesis as expected but also the delay in furrow initiation and the slow furrow ingression phenotypes characteristic of *cyk-4(or749ts)* embryos were largely corrected ([Figure 6B,Cii](#fig6){ref-type="fig"}). Thus, unlike *ced-10(n1993), ect-2(xs110)* suppresses the primary defect of the *cyk-4(or749ts)* mutation.

To confirm that the *ect-2(xs110)* substitution was causative, we used the CRISPR-associated nuclease Cas9 to re-create this mutation ([@bib48]). We injected *cyk-4(or749ts)* animals with a plasmid that expresses both Cas9 and a sgRNA designed to create a double strand break near E705 and provided an oligonucleotide repair template containing the G707D substitution. The animals were maintained at the permissive temperature for two generations before shifting to the restrictive temperature. We were able to isolate a strain that was viable and fertile. The *ect-2* locus was sequenced and de novo generation of the G707D substitution was confirmed. This mutation in *ect-2* therefore suppresses all the essential functions affected by the *cyk-4(or749ts)* allele.

We next investigated whether this mutation causes a detectable phenotype when separated from *cyk-4(or749ts)*. Interestingly, *ect-2(xs110)* embryos exhibit hypercontractility during both pseudocleavage and cytokinesis ([Figure 6Bi](#fig6){ref-type="fig"}); this hypercontractility is associated with enhanced cortical accumulation of myosin II ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). Hypercontractility is also observed in embryos from *ect-2(xs110)/+* hermaphrodites, indicating *ect-2(xs110)* is a dominant, gain of function allele ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). The hypercontractility is reduced in *ect-2(xs110)*; *cyk-4(or749ts)* embryos (ii), indicating that ECT-2^G707D^ hyperactivity is partially dependent on CYK-4 and that *cyk-4(or749ts)* and *ect-2(xs110)* exhibit mutual suppression. Comparison of *ect-2(xs110); cyk-4(or749ts)* embryos to *ect-2(xs110); cyk-4(or749ts); nop-1(RNAi)* ([Figure 6ii](#fig6){ref-type="fig"} vs [Figure 6iii](#fig6){ref-type="fig"}) embryos reveals that NOP-1 also contributes to contractility in ECT-2^G707D^ embryos.

An unusual phenotype was observed in *ect-2(xs110)* embryos. Following anaphase, the cleavage furrow frequently initiates from a site significantly anterior to the midpoint of the anaphase spindle ([Figure 6D--F](#fig6){ref-type="fig"}). As the furrow ingresses, it undergoes a dramatic repositioning so that it ultimately bisects the anaphase spindle. Nevertheless, the *ect-2(xs110)* strain is viable and fertile despite exhibiting hypercontractility during polarization and cytokinesis ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

The second suppressor allele, *ect-2(xs111)*, also contains a substitution mutation in ECT-2. This mutation is located in the linker region between the cryptic BRCT0 domain and BRCT1 ([@bib53]) ([Figure 6A](#fig6){ref-type="fig"}). Several criteria indicate that this mutation is also causal. First, SNP mapping placed suppressor activity near the *ect-2* locus. Second, the suppressor was analyzed by one step mapping and whole genome sequencing ([@bib12]). *ect-2* is the only gene in the candidate region that contained a non-silent mutation that has any role in cytokinesis. Third, biochemical data indicate that this mutation relieves ECT-2 autoinhibition (see below). The *ect-2(xs111)* gain of function allele exhibited similar overall characteristics as *ect-2(xs110)* ([Figure 6B,C](#fig6){ref-type="fig"}), although the spindle positioning defect was less severe (not shown)*.* The one remarkable difference was that *ect-2(xs111); cyk-4(or749ts); nop-1(RNAi)* ([Figure 6Bviii](#fig6){ref-type="fig"}) embryos fully ingressed during cytokinesis, though they do not form pseudocleavage furrows. The ability of these embryos to complete cytokinesis depends upon residual activity from CYK-4^E448K^, as depletion of CYK-4 by RNAi prevents completion of cytokinesis in *ect-2(xs111)* embryos ([Figure 6Bx](#fig6){ref-type="fig"}). As complete furrow ingression is not seen in comparable *ect-2(xs110)* embryos ([Figure 6Biii](#fig6){ref-type="fig"}), *ect-2(xs111)* may be more strongly activated than *ect-2(xs110).*

This genetic screen demonstrates that only rare mutations suppress *cyk-4(or749ts)* and that the essential function of CYK-4 that is inactivated by CYK-4^E448K^ is the ability to activate RhoA. Note that while *ced-10(n1993)* can partially suppress cytokinesis defects in CYK-4^E448K^ expressing embryos (cytokinesis remains delayed and slow in the double mutant; and only ∼67% of embryos complete division), *ced-10(n1993)* does not rescue *cyk-4(or749ts)* to viability ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

CYK-4^R459A^ causes a less severe phenotype than CYK-4^E448K^, therefore we predicted that *ect-2(xs110)* and *ect-2(xs111)* could also suppress CYK-4^R459A^. We used CRISPR/Cas9 to introduce the R459A mutation into the endogenous *cyk-4* gene and crossed it into both *ect-2* hyperactive mutants. We were able to isolate strains in which the sole source of CYK-4 lacks the critical arginine in the active site ([Figure 6Biv,ix](#fig6){ref-type="fig"}). The resulting strains exhibited high viability and fertility ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). This finding provides independent confirmation that the sole essential function of the RhoGAP active site of CYK-4 is to stimulate ECT-2-mediated RhoA activation.

*cyk-4* suppressor mutations activate *ect-2* {#s2-9}
---------------------------------------------

These genetic and cell biological results demonstrate that the GAP activity of CYK-4 contributes to RhoA activation. As ECT-2 is required for all RhoA activity during cytokinesis, the CYK-4 GAP domain is likely to serve this role by modulating ECT-2. Given that the canonical function of a RhoGAP domain is to inhibit RhoA activity, it is surprising that a protein containing a RhoGAP domain enhances RhoA activation. However, CYK-4 and ECT-2 form a protein complex through their regulatory N-termini ([@bib4]; [@bib43]), therefore the C-terminal GAP domain of CYK-4 will be in the vicinity of the ECT-2 RhoGEF domain.

We therefore hypothesized that the interactions between CYK-4 and ECT-2 are not limited to their N-termini. To test this, we purified the C-terminal domains of CYK-4 and ECT-2 ([Figure 7A](#fig7){ref-type="fig"}) and performed binding assays. We found that the catalytic C-termini of CYK-4 and ECT-2 directly interact ([Figure 7B](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}); a similar complex is also found with human orthologs (data not shown). We assayed for activation of the ECT-2 GEF activity by the CYK-4 GAP domain in vitro. However, we have not yet been able to detect stimulation of GEF activity (data not shown). This negative result could be due to missing components, a requirement for the context provided by the full length, oligomerization competent proteins ([@bib1]), or the absence of the plasma membrane to which CYK-4 must bind in vivo in order to activate ECT-2.10.7554/eLife.08898.025Figure 7.Biochemical basis for suppression by ECT-2 variants.(**A**) Schematic depiction of the domain organization of CYK-4 and ECT-2 and the recombinant fragments used for biochemical analyses. (**B**) GST pulldown between GST-ECT-2 DHPH and CYK-4 C1GAP. (**C**) Pulldown assay between MBP-ECT-2-N (wild-type and the E129K variant) with GST-ECT-2 DHPH (both wild-type and the G707D variant). The MBP proteins were present in the soluble fraction and incubated with the GST-DHPH fragments bound to beads. The wild-type N-terminus associates with wild-type and G707D C-termini. However, the ECT-2 N^E129K^ is defective in binding to wild-type C-terminus. (**D**) The G707D substitution activates the exchange activity of ECT-2. Exchange assays were performed with RhoA•GDP exchanging for mant-GTP at different concentrations of ECT-2 DHPH and ECT-2 DHPH^G707D^. Results shown are the average (±s.e.m) of three assays. The gel contains 1 µg of each ECT-2 variant and a BSA standard. (**E**) Working model summarizing the proposed mechanism for ECT-2 activation. Note that only the CYK-4 subunit of centralspindlin is shown. In vivo, centralspindlin is predicted to be oligomeric and the entire complex bound to the plasma membrane.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.025](10.7554/eLife.08898.025)10.7554/eLife.08898.026Figure 7---figure supplement 1.Biochemical characterization of CYK-4 and ECT-2 variants.(**A**) GST-pulldown assay between GST-ECT-2 DHPH and CYK-4 GAP/C. Wild-type, R459A, and EE variants of CYK-4 GAP exhibit similar binding activity to GST-ECT-2 DHPH but do not bind to GST alone. (**B**) GST-pulldown assay between GST-ECT-2 DHPH (wild-type and G707D variant) and MBP- ECT-2-N (wild-type and E129K variant). The wild-type N-terminus associates with wild-type and G707D DHPH, whereas ECT-2 N E129K is defective in binding to wild-type DHPH. Neither MBP-ECT-2-N variant binds to GST alone. (**C**) Proteins used in binding assays.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.026](10.7554/eLife.08898.026)10.7554/eLife.08898.027Figure 7---figure supplement 2.Proposed states of the ECT-2/CYK-4 complex.(**A**) Correspondence between the *cyk-4* genotypes, the proposed forms of the CYK-4:ECT-2 complexes, and the observed levels of contractility. (**B**) Schematic depicting the mechanism of activation of p115-RhoGEF by its RGS homology domain and G alpha 13 (based on small angle x-ray scattering analysis) compared to the proposed working model for ECT-2 activation.**DOI:** [http://dx.doi.org/10.7554/eLife.08898.027](10.7554/eLife.08898.027)

As *ect-2(xs110)* and *ect-2(xs111)* suppress the phenotypes caused by mutations in the CYK-4 GAP domain, we sought to understand the biochemical basis of activation by the proteins they encode, ECT-2^G707D^ and ECT-2^E129K^, respectively. Given that the E129K mutation lies near the N-terminal BRCT domain ([Figure 7A](#fig7){ref-type="fig"}), we hypothesized that it could interfere with ECT-2 autoinhibition. To test this possibility, we assayed for binding between the N- and C- termini of ECT-2. Wild-type N- and C- termini form a complex that is readily detected in vitro. However, the E129K substitution, but not G707D, significantly reduces binding of the ECT-2 N- and C-termini ([Figure 7C](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}), suggesting that this allele functions by relieving autoinhibition.

The G707D mutation in ECT-2 is located in the PH portion of the RhoGEF domain ([Figure 7A](#fig7){ref-type="fig"}, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). In principle, this mutation could promote RhoA activation by a number of mechanisms including activation of the GEF domain, relieving autoinhibition of ECT-2, stabilizing the interaction with CYK-4 and/or stabilizing the interaction of ECT-2 with the plasma membrane. We did not observe a change in the association of ECT-2_N with ECT-2_C^G707D^, suggesting that the mutation doesn\'t relieve autoinhibition. However, as the mutated residue maps to a helix that lies near RhoA in a co--crystal structure of a related RhoGEF ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), we tested whether it activates RhoGEF activity. We assayed ECT-2 GEF activity in an in vitro exchange assay. The ECT-2^G707D^ variant exhibits a modest increase in GEF activity compared to wild-type ECT-2 over a range of concentrations ([Figure 7D](#fig7){ref-type="fig"}), perhaps by increasing the affinity of ECT-2 for RhoA.

Discussion {#s3}
==========

Overview {#s3-1}
--------

Diverse mechanisms ensure that the cytokinetic contractile ring assembles at the cell equator following chromosome segregation. These regulatory mechanisms converge to promote local accumulation of active RhoA at the cell equator which is an essential prerequisite for contractile ring assembly. Whereas it is widely accepted that the RhoGEF ECT-2 is the primary activator of RhoA and the centralspindlin component CYK-4 contributes to RhoA activation, the mechanism(s) by which CYK-4 promotes RhoA activation have been rather unclear. Here, we demonstrate that CYK-4 has multiple functional domains that are required for it to promote RhoA activation. In addition to the previously characterized binding interaction with ECT-2, we show that both the C1 domain and the catalytic activity of the RhoGAP domain of CYK-4 are also required for full activation of ECT-2. Furthermore, our results indicate in order for the CYK-4 GAP domain to promote RhoA activation, it has to act catalytically on RhoA•GTP. This implies that RhoA plays a role in promoting its own activation.

The GAP activity of CYK-4 is required for RhoA activation {#s3-2}
---------------------------------------------------------

Four results suggest that CYK-4 GAP activity promotes RhoA activation. First, CYK-4 GAP activity is required for the completion of cytokinesis and embryos lacking this activity exhibit reduced levels of RhoA effectors. Second, when the NOP-1-dependent, parallel pathway for RhoA activation is eliminated, the requirement for CYK-4 GAP activity for furrow formation and effector recruitment is greatly enhanced. Third, we have demonstrated a biochemical interaction between the GAP domain of CYK-4 and the GEF domain of ECT-2. Fourth, the requirement for CYK-4 GAP activity can be alleviated by three independent perturbations that each increase RhoA activity levels.

One of the perturbations that suppresses the CYK-4 GAP-deficient phenotype is depletion of the primary RhoA GAP, RGA-3/4. Embryos defective in RGA-3/4 alone exhibit hypercontractility and are largely inviable; these phenotypes are consistent with the canonical function of a RhoA GAP. However, loss of CYK-4 GAP activity and loss of RGA-3/4 counterbalance each other during cytokinesis. Furthermore, suppression by RGA-3/4 depletion is potent, it can restore cytokinesis in embryos deficient in both NOP-1 and CYK-4 GAP activity in which furrows otherwise barely ingress.

A large, unbiased, genome-wide screen for suppressors of *cyk-4(or749ts)* corroborates the model that CYK-4 GAP activity promotes RhoA activation. We identified two strong, extragenic, gain of function suppressor mutations in the RhoGEF ECT-2 ([Figure 6](#fig6){ref-type="fig"}). Because these suppressors rescue *cyk-4(or749ts)* and *cyk-4^R459A^* to viability, the essential function of the CYK-4 GAP activity must be to promote RhoA activation.

Mechanism of ECT-2 activation and positive feedback {#s3-3}
---------------------------------------------------

These results raise the fundamental question: by what mechanism does the GAP activity of CYK-4 contribute to RhoA activation? We propose a working model in which the most active form of the ECT-2 RhoGEF is a complex containing ECT-2 and CYK-4 with a molecule of RhoA•GDP bound to the GAP active site ([Figure 7E](#fig7){ref-type="fig"}).

The GTPase bound to CYK-4 is likely to be RhoA, rather than CED-10/Rac1 or CDC-42. If CYK-4 had to bind CED-10/Rac1 or CDC-42, then depletion of those GTPases should impair cytokinesis as severely as a mutation that attenuates GTPase binding by the CYK-4 GAP domain. However, neither CED-10/Rac1 nor CDC-42 is required for cytokinesis, even in NOP-1-defective embryos ([Figure 3](#fig3){ref-type="fig"}), whereas weakening GTPase binding by the CYK-4 GAP domain strongly impacts cytokinesis. The model has a further implication: to form the most active ECT-2 GEF complex, CYK-4 GAP binds RhoA•GTP. Therefore, RhoA•GTP plays a role in RhoGEF activation, suggesting the presence of a positive feedback loop during cytokinesis.

This working model is supported by the finding that full activation of RhoA and cytokinesis requires that the CYK-4 GAP domain both bind a Rho family GTPase ([Figure 3](#fig3){ref-type="fig"}) and activate its ability to hydrolyze GTP ([Figures 2, 4, 5](#fig2 fig4 fig5){ref-type="fig"}); indeed mutations in the CYK-4 GAP domain that diminish GTPase binding exhibit a stronger defect in RhoA activation than mutation of the GAP active site ([Figure 5](#fig5){ref-type="fig"}). Our mutational analysis has trapped ECT-2 in four distinct states that form an allelic series ([Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}). We propose that the least active form of ECT-2 is not bound to CYK-4 and has little GEF activity. Once CYK-4 is phosphorylated, it can be bound by the ECT-2 N-terminal BRCT domains rendering it weakly activated (equivalent to CYK-4^EE^). This form may also exhibit some interactions between the GEF domain of ECT-2 and the GAP domain of CYK-4, as these domains can interact in vitro without RhoA present. If CYK-4 can bind to RhoA•GTP, it induces a higher activity state, as evidenced by the increased activity of CYK-4^R459A^, which is sufficient for zygotic development. Finally, if CYK-4 can induce GTP hydrolysis by RhoA, this results in the fully active ECT-2/CYK-4/RhoA•GDP or ECT-2/CYK-4/RhoA•GDP + Pi state populated by the wild-type protein. We speculate that this complex results in full relief from autoinhibition within the ECT-2 GEF domain.

Not only does this model explain why CYK-4 retains GAP activity towards RhoA, it also explains why its ability to inactivate RhoA is attenuated relative to Rac and Cdc42. High turnover rates of RhoA•GTP induced by CYK-4 might rapidly consume RhoA•GTP at the site of production, yielding a futile cycle of RhoA activation and inactivation. However, this working model must be tested by structural studies and biochemical reconstitution assays that reflect the in vivo situation. Accurate reconstitutions will need to account for the facts that cytokinetic RhoA activation involves the CYK-4 C1 domain ([Figure 1C](#fig1){ref-type="fig"}), the ability of CYK-4 to bind to ZEN-4, and the ability of ZEN-4 to oligomerize ([@bib1]).

CED-10/Rac1 is not the primary target for CYK-4 GAP activity {#s3-4}
------------------------------------------------------------

We tested the model that GAP activity of CYK-4 is important to maintain CED-10/Rac1 in an inactive state. Some of our results do support this model, as the failure to complete the first cytokinesis in embryos lacking CYK-4 GAP activity can be partially restored by a loss of function mutation in *ced-10/Rac1* ([Figure 4B](#fig4){ref-type="fig"}). We therefore tested whether inactivation of CED-10/Rac1 suppresses loss of CYK-4 GAP activity in NOP-1-deficient embryos. GAP-deficient CYK-4 does not promote significant ingression of the cleavage furrow in embryos lacking NOP-1, irrespective of the presence or absence of CED-10/Rac1 ([Figure 4Biii,v](#fig4){ref-type="fig"}). Finally, mutations in CED-10/Rac1 do not suppress the lethality of a temperature sensitive mutation in *cyk-4* ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

Thus, because the active site of the CYK-4 GAP domain is required in the absence of CED-10/Rac1, CED-10/Rac1 inactivation cannot be the primary function of the CYK-4 GAP domain. Rather, these results suggest a model in which loss of CED-10/Rac1 function causes a reduction in overall cortical tension which, in turn, allows an increase in the extent of NOP-1-dependent furrow ingression ([@bib27]).

GEF activation model can account for many previous results {#s3-5}
----------------------------------------------------------

The experiments presented here demonstrate that CYK-4 GAP activity promotes RhoA activation and that this function is essential in early *C. elegans* embryos and in the adult germline ([Figures 2A, 4B](#fig2 fig4){ref-type="fig"}). Our experiments also addressed the function of CYK-4 GAP activity post-embryonically. We find that whereas zygotic *cyk-4* null embryos die during embryogenesis, expression of catalytically inactive CYK-4 provides significant rescue, supporting development into viable, albeit sterile, adults ([Figure 2A](#fig2){ref-type="fig"}). Thus, while early embryos require the GAP activity of CYK-4, this requirement is relaxed post-embryonically. The requirement for CYK-4 GAP activity can be experimentally eliminated by hyperactivation of ECT-2 or depletion of the RhoA GAP RGA-3/4 ([Figures 5B, 6B](#fig5 fig6){ref-type="fig"}). Interestingly, RGA-3/4 is primarily expressed in the germline and in early embryos (NextDB, cited in [@bib32] and data not shown), thus regulated RGA-3/4 expression could contribute to the tissue specific requirements.

These findings allow us to reconcile many previous results on the role of the CYK-4 GAP domain during cytokinesis. Some studies provided evidence that the GAP activity is dispensable ([@bib17]; [@bib44]), whereas others suggested it is required for Rac1 inactivation ([@bib10]; [@bib7]; [@bib2]), RhoA inactivation ([@bib28]), or RhoA activation ([@bib10]; [@bib47]; [@bib27]). The first set of results is consistent with the results presented here, as some cell types may not require the GAP activity of CYK-4 for cytokinesis, as seen in post embryonic cells in *C. elegans*. As numerous studies have shown that active RhoA can indirectly inhibit Rac1 (see [@bib19] for review), some of the results that point to a role for CYK-4 GAP activity in attenuating Rac1 levels ([@bib2]) may be indirectly caused by a reduction RhoA activation or by indirectly controlling cortical tension. Thus, many previous results can be explained without proposing that the CYK-4 GAP domain performs different functions in different organisms or cell types. We do not rule out the possibility that, in certain contexts, CYK-4 or its orthologs negatively regulate Rac or Cdc42. Recent evidence indicates that the *Xenopus* ortholog of CYK-4 concentrates at cell--cell junctions and negatively regulates GTPases at that site ([@bib5]). Further work is required to resolve why CYK-4 acts as a positive regulator of RhoA in *C. elegans* embryos and a negative regulator in *Xenopus* embryos ([@bib28]; [@bib5]).

Regulation of RhoGEFs by GTPases and GAPs {#s3-6}
-----------------------------------------

The signaling mechanisms we have discovered in cytokinesis have analogies in other signaling pathways. Our favored model, in which RhoA promotes its own activation, is reminiscent of the positive feedback in Cdc42 activation during yeast budding ([@bib21]) and the activation of the SOS1 RasGEF domain by a molecule of Ras•GTP that serves as an allosteric activator ([@bib20]). Interestingly, ECT-2 has also been implicated in SOS regulation ([@bib6]). Likewise, CYK-4 is not the only protein with a GTPase activating domain that plays a role in promoting GEF activity. A similar function, in cis, has been seen in p115 RhoGEF, which is activated by Gα13 ([@bib8]). In this case, the binding of a molecule of Gα13 to an allosteric site on the RhoGEF domain of p115 is stabilized by p115\'s N-terminal RGS domain ([Figure 7---figure supplement 2B](#fig7s2){ref-type="fig"}). RGS domains accelerate GTP hydrolysis by Gα, that is, they are Gα GAPs ([@bib38]). As RhoGEF activation is not an obvious function for a RhoGAP domain, additional cases may have gone undetected.

Complex control of RhoA activation during cytokinesis {#s3-7}
-----------------------------------------------------

RhoA activation is controlled by multiple layers of regulation during cytokinesis. In addition to cell-cycle regulated changes in the phosphorylation state of CYK-4 and ECT-2 that control their binding and localization ([@bib45]; [@bib36]; [@bib53]), full activation of RhoA also involves membrane binding by CYK-4 ([Figure 1](#fig1){ref-type="fig"}) which, in turn, requires centralspindlin oligomerization ([@bib1]). Like the requirement for CYK-4 GAP activity, the requirement for the C1 domain of CYK-4 is context dependent. Whereas the C1 domain makes a major contribution to furrow ingression in *C. elegans* embryos, studies in Hela cells demonstrate that the C1 domain contributes to RhoA activation, but it is not essential ([@bib26]). Thus, centralspindlin has several domains that contribute to maximal activation of ECT-2. However, not all cell types may require maximal activation of ECT-2 either because of physical properties of the cell (cell size, cortical tension, and tissue organization) or because of their biochemical properties (expression of RGA-3/4 orthologs). Nevertheless, the evolutionary conservation of all of these functions suggests that they play critical roles during some stage(s) of metazoan development.

Materials and methods {#s4}
=====================

*C. elegans* strains {#s4-1}
--------------------

Animals were grown at 20°C on standard nematode growth media (NGM) plates seeded with OP50 *Escherichia coli*. Some strains were provided by the Caenorhabditis Genetics Center. All strains used in this study are listed in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.

RNAi {#s4-2}
----

RNAi was administered by feeding nematodes with *E. coli* expressing the appropriate double-stranded RNA (dsRNA) ([@bib39]). HT115 bacterial cultures were grown in Luria broth with 100 μg/ml ampicillin overnight at 37°C. Cultures (250 μl) were seeded on NGM plates containing 100 μg/ml ampicillin and 1 mM IPTG and incubated at room temperature for 16 hr. RNAi plasmids were obtained from the library produced by [@bib23]. Young L4 hermaphrodites were picked onto the plates for feeding at 25°C at least 24 hr prior to dissection. For RNAi depletion of temperature-sensitive alleles, L4 larvae were fed for 48 hr at 16°C, then shifted to 25°C for at least 1 hr before imaging.

For experiments where two genes were simultaneously knocked down by RNAi, bacterial cultures of *E. coli* expressing the appropriate dsRNA were mixed in a 1:1 ratio seeded onto NGM plates as described above. If stronger depletion of one of the two genes was desired, embryos were first hatched onto feeding plates targeting the gene. L4 worms were transferred to fresh plates with bacteria expressing dsRNA against both genes.

Egg hatch assay {#s4-3}
---------------

Young gravid hermaphrodites were transferred to fresh seeded NGM plates in triplicate. Remove worms from plates after ∼8 hr of egg laying. The eggs laid on plates were scored manually under dissecting microscope. To determine unhatched embryos, embryos remaining on plates were scored 1 day after the parents were removed. The embryonic lethality percentage is calculated as the number of unhatched embryos divided by the total egg production.

Plasmid construction {#s4-4}
--------------------

To generate CYK-4::GFP MosSCI constructs, ∼2 kb sequences upstream of *cyk-4*, *cyk-4* genomic DNA tagged with C-terminal GFP coding sequences, and *pie-1* 3′ UTR sequences were generated by overlapping PCR and inserted to pCFJ150 by SLiCE ([@bib49]). *cyk-4* genomic sequences between BamHI and AvrII were recoded to generated RNAi resistant alleles. To introduce *cyk-4* mutations, sequences covering mutations were generated by overlapping PCR using pCJF150-cyk-4-gfp as template and the appropriate primers (see primer sequences in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}): MG4199/MG4276 and MG4200/MG4277 for E448K; MG4199/MG4202 and MG4200/MG4201 for R459A; MG4199/MG4489 and MG4200/MG4488 for K459E/R499E(EE); MG4199/MG4070 and MG4200/MG4071 for ∆C1. Overlapping PCR products were inserted into pCFJ15-cyk-4-gfp linearized with NaeI by SLiCE. All constructs were sequence verified.

Cas9/sgRNA plasmids were derived from pDD162 vector ([@bib11]). *ect-2* sgRNA target sequences were generated by overlapping PCR using pDD162 as PCR template and the appropriate primers (see primer sequences in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}), MG4735/MG4773 and MG4774/MG4736. Overlapping PCR products were inserted into pDD162 linearized with SpeI/BsrBI by SLiCE.

Transgenes and germline transformation {#s4-5}
--------------------------------------

Transgenic lines expressing single copy CYK-4::GFP or mutant CYK-4::GFP were generated by integrating constructs into the Mos1 element ttTi5605 on chromosome II using the MosSCI method ([@bib16]).

For oligonucleotide templates (ODNs) based CRISPR experiments ([@bib48]; [@bib50]), microinjection was performed by injecting DNA mixture into gonad arms of *cyk-4(or749ts)* young gravid hermaphrodites. Injected *cyk-4(or749ts)* were maintained at 16°C for 3--4 days then shifted to 25°C until starvation. Viable worms were isolated and subjected to single worm PCR to identify desired mutations. The injection mixture consists of Cas9/sgRNA plasmids and ODNs. The final concentrations of plasmids and ODNs are Cas9/ect-2 sgRNA vector at 50 ng/μl and *ect-2* ODN (MG4801 5′-TTGTATGGTGCCTGATTCATCGTGACGAGCAAGATGGTGACATTGACACAGTCTTCGAAT-3′) at 50 ng/μl.

Microscopy {#s4-6}
----------

To prepare one-cell embryos for imaging, gravid hermaphrodites were dissected into egg salt buffer (HEPES pH 7.4 5 mM, NaCl 118 mM, KCl 40 mM, MgCl~2~ 3.4 mM, CaCl~2~ 3.4 mM) on coverslips, mounted onto 2.5% agar pads and sealed with vaseline. For Nomarski imaging, embryos were observed with a Zeiss (Thornwood, NY) Axioplan II with a 100×/1.3 Plan-Neofluar objective. Images were captured with a charge-coupled device (CCD) camera (Imaging Source, Charlotte, NC) controlled by Gawker ([gawker.sourceforge.net](http://gawker.sourceforge.net)). Images were acquired every 5 s and processed with ImageJ (<http://rsbweb.nih.gov/ij>). For confocal imaging, embryos were imaged with a 63×/1.4 oil-immersion lens on (1) a Zeiss Axiovert 200M equipped with a Yokogawa CSU-10 spinning-disk unit (McBain, Simi Valley, CA) and illuminated with 50-mW, 473-nm and 20-mW, 561-nm lasers (Cobolt, Solna, Sweden), or (2) a Zeiss Axioimager M1 equipped with a Yokogawa CSU-X1 spinning-disk unit (Solamere, Salt Lake City, UT) and illuminated with 50-mW, 488-nm and 50-mW, 561-nm lasers (Coherent, Santa Clara, CA). Images were captured on a Cascade 1K EM-CCD camera or a Cascade 512BT (Photometrics, Tucson, AZ) controlled by MetaMorph (Molecular Devices, Sunnyvale, CA). Image processing was performed with ImageJ. Time-lapse acquisitions were assembled into movies using Metamorph and ImageJ.

Image quantification {#s4-7}
--------------------

To measure furrow ingression kinetics, a single central plane image of GFP::PH or mCherry::PH was acquired at 10 s intervals starting at anaphase as assessed by the CYK-4::GFP or mCherry::HIS-58 signal. The position of the furrow was assessed in each frame by manual tracking of GFP::PH or mCherry::PH signal. The extent of ingression in each frame was calculated as d/w, where w is the total width of the embryo and d is the distance between the furrow tips. To determine whether furrow ingression kinetics were statistically significant different between multiple genotypes, data sets of normalized cortical distance from 100 s to 410 s after anaphase onset were analyzed with a Kruskal--Wallis non-parametric one-way analysis of variance (ANOVA) using Dunnett\'s multiple comparisons test.

To quantitate the abundance of NMY-2::mRFP at the equatorial region, a stack of five planes spanning 2.5 μm was captured every 10 s. The Z-stacks were projected using a maximum intensity projection algorithm and corrected for photobleaching. Using custom ImageJ macros, the background signal was measured in a remote region of each frame. A region of fixed size in the equatorial region was thresholded with a minimal value of 1.25× background and the total thresholded signal in the region was integrated and normalized to the background. The total value of intensity was summed for a defined number of planes after anaphase onset.

To quantitate the abundance of CYK-4::GFP at the furrow tip, a stack of five planes spanning 2.5 μm was captured every 10 s. The frame in which furrow ingressed to half of the egg width or the deepest was chosen. The Z-stacks were projected using a maximum intensity projection algorithm and corrected for photobleaching. The background was measured as integrated intensity of a square adjacent to the furrow tip. The GFP intensity was measured as integrated intensity of a square with the same area covering the furrow tip and normalized to the background by subtracting background intensity (see [Figure 1](#fig1){ref-type="fig"}).

Protein expression and purification {#s4-8}
-----------------------------------

The coding sequences for CYK-4 C1 and RhoGAP domain (342-681aa), ECT-2 DH/PH domain (356-792aa), CED-10/Rac1 and RhoA (*C.e.*) were cloned into the GST expression vector pGEX-4T-tobacco etch virus (TEV), and the coding sequences for ECT-2 BRCT domain (1-363aa) were cloned into MBP expression vector pMAL-c2-TEV. GST- and MBP-tagged proteins were expressed in *E. coli* strain BL21 by adding 0.3 mM IPTG at OD600 reached 0.5--0.7 at 25°C. Cells were grown for another 4 hr at 25°C and collected. Frozen cells were thawed in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl~2~, 10% Glycerol, 1 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml pepstatin A, 0.1% Triton X-100, 1 mM DTT, 0.5 mg/ml lysozyme) and lysed by sonication. The bacterial lysate was centrifuged at 40,000×*g* at 4°C for 30 min.

For GST-tagged proteins, glutathione-Sepharose 4B beads (bioWORLD) were added to supernatant and incubated at 4°C for 4 hr. The beads were washed 3× with 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl~2~, 1 mM DTT. Protein-bound beads in were either stored in 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl~2~, 1 mM DTT, 50% glycerol at −20°C, or cleaved from beads by incubation with His-tagged TEV protease at 4°C overnight. TEV protease was removed by incubation with TALON beads (Clontech). Cleaved fusion proteins were stored in 10% glycerol at −80°C.

For MBP-tagged proteins, amylose resin (New England Biolabs) was added to supernatant and incubated at 4°C for 4 hr. Beads were placed in a poly-prep chromatography column (Bio-Rad), and washed with 12 column volumes of 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl~2~, and 1 mM DTT. Fusion proteins were eluted with 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl~2~, 1 mM DTT, 10 mM maltose, and stored in 10% glycerol at −80°C.

GEF activity measurements {#s4-9}
-------------------------

*C.e.* GST*-*RhoA was loaded with GDP ([@bib35]). Beads were washed with low magnesium buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM DTT) and 1 mM GDP was added. Beads were incubated with shaking at room temperature for 15 min, placed on ice, and 20 mM MgCl~2~ was added and incubated on ice for 5 min. Beads were washed three times with 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl~2~, 1 mM DTT. GDP-loaded RhoA was cleaved from beads with TEV protease, glycerol added to 10%, flash frozen and stored at −80°C.

Fluorescence-based kinetic assays were performed in HORIBA FluoroLog-3 Spectrofluorometer, with fluorescence analog of GTP, mant-GTP (AnaSpec). All nucleotide exchange assays were performed in the presence of 1 μM RhoA-GDP, 200 nM mant-GTP, the indicated concentration of ECT-2 DH/PH domain in 20 mM Tris pH 7.5, 50 mM NaCl, 10 mM MgCl~2~, 1 mM DTT, 50 μg/ml BSA, 1% glycerol. The relative fluorescence was monitored for 90 s before adding mant-GTP, and for 510 s after adding mant-GTP; measurements were taken every 15 s. The reaction rate, v, is defined as ∆F/∆t, where F = fluorescence, t = time.

RhoGAP assay {#s4-10}
------------

CYK-4 GAP (final concentration from 0 to 800 nM) and RhoA or Rac1 (final concentration 9 μM) were mixed in 1× reaction buffer (50 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl~2~, 1 mM DTT, 1% glycerol), then GTP was added to 1 mM to start the reaction. After 30 min, inorganic phosphate was assayed using a malachite green-based assay ([@bib25]); absorbance was measured with a NanoDrop 2000 spectrophotometer (Thermo Scientific). For time course experiments, 200 nM CYK-4 GAP was added into the reaction and, at the indicated time points, aliquots of the reaction were removed to assess free phosphate.

GST pull-down assay {#s4-11}
-------------------

For each binding experiment, purified fusion proteins were added to the protein-bound glutathione-sepharose beads and incubated for 1 hr at 4°C. After three washes in cold wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl~2~, 1 mM DTT), proteins were eluted into loading buffer, separated by SDS-PAGE, and detected by coomassie blue staining.
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Thank you for submitting your work entitled "The RhoGAP activity of CYK-4/MgcRacGAP functions non-canonically by promoting RhoA activation during cytokinesis" for peer review at *eLife*. Your submission has been favorably evaluated by Randy Schekman (Senior Editor) and three reviewers, one of whom, Mohan Balasubramanian, is a member of our Board of Reviewing Editors.

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As you see, the views were varied (but all supportive), and Reviewer 3 has raised a number of technical issues all of which seem reasonable and I would like you to consider and respond to these comments. In particular: 1) please provide in vivo data to address key points of Reviewer 3 (such as potential effect of remaining Rac activities; RAC-2 or MIG-2), and 2) please provide proper controls for in vitro experiments raised by Reviewer 3.

As for Reviewer 2, although the biochemical experiments are ultimately required to advance your model further, this may not be accomplished in a single paper and may not be possible within the timeframe of the revision. If you have made some progress since submission of your paper and if they address the mechanism of GAP activation of ECT2, you may add it.

Please also address the points of Reviewer 1, most of which seem to be aimed at improving the readability as well as placing the paper in the right context through further discussion. Please see below the comments of the three reviewers.

Reviewer \#1:

This is an interesting paper by Glotzer and colleagues in which they have investigated the function of CYK-4 GAP protein in *C. elegans* cytokinesis. Through structure-function analysis of CYK-4 GAP they have identified that the GAP activity of CYK-4 is essential for cytokinesis, and performs at least 2 different functions. They make the important discovery that the GAP activity is crucial for nucleotide exchange on RhoA, the GTPase that activates both actin polymerization and myosin II activation. The work is very thorough and I particularly like the experiment where, through an unbiased screen for suppressors of CYK-4 GAP mutants, they identify new alleles of the RhoA exchange factor ECT2 itself. They further go on to show that CYK-4 physically interacts with ECT-2 and that an Ect2 mutant they isolated has higher nucleotide exchange activity (albeit a modest one).

I think the paper is appropriate for publication in *eLife*. However, I would like to see the biochemistry developed better. In particular, I am surprised that none of the GAP mutants identified in the work have been characterized in the biochemical studies described in the latter part of the paper. The two key experiments are: 1) how do the GAP mutants behave in the physical interaction experiments with ECT2 and 2) how does the presence of wild-type or GAP mutants of CYK-4 affects the ECT2-mediated nucleotide exchange on RhoA. These experiments are crucial if they are to advance the model in [Figure 7](#fig7){ref-type="fig"}.

I think some more discussion is also warranted on how mutations in the PH domain potentially affect the GEF activity. Molecular dynamics may help, although I realize this can be a new foray altogether.

Reviewer \#2:

Zhang and Glotzer provide an extensive and compelling analysis of the controversial role of the *C. elegans* RhoGAP CYK-4 during cytokinesis in animal cells. Their data strongly support the conclusion that the primary role of CYK-4/RhoGAP is to activate RhoA through its RhoGEF ECT-2. This is a counter-intuitive finding, as normally one thinks of GAPs as negative regulators of GTPases, not activators. The authors provide a rationale for this surprising role, and their evidence certainly supports the conclusion and also can to a large extent explain alternative views (invoking either indirect effects on other GTPases, or indirect effects from depletion of other GTPases to explain results suggesting that either the GAP activity of this family of RhoGAPs is not necessary or that it acts on other GTPases, in particular Rac as reported by [@bib7]). The authors provide an elegant and impressive analysis of this issue, using a powerful combination of mutational analysis, live cell imaging and biochemistry. This manuscript provides the most extensive and compelling analysis of how CYK-4 influences cytokinesis via the RhoGEF ECT-2 and the RhoA GTPase, and should go a long ways toward resolving this complex issue.

While the manuscript in my opinion clearly warrants publication in *eLife*, the authors first need to address the following concerns that, while perhaps relatively minor, nevertheless could possibly improve the clarity of their arguments.

1\) In the Introduction, subsection "The role of the GAP activity of CYK-4 GAP has been controversial", the authors point out that CYK-4 has GAP activity toward RhoA but much more toward Rac1 and CDC-42. The authors should directly address how these observations relate to their conclusions concerning their model for how CYK-4 functions as an activator of RhoA.

2\) With respect to [Figure 1](#fig1){ref-type="fig"}, the authors should discuss why there is some furrow ingression in embryos expressing CYK-4 lacking the C1 domain, and lacking *nop-1* and *ced-10* (in contrast to CYK-4^E448K^).

3\) In two places (subsection "The *cyk-4(or749ts)* allele, E448K, exhibits defects in membrane association" and "CYK-4 GAP domain mutations that prevent RhoA binding are highly defective in RhoA activation"), the authors conclude results paragraphs by stating that an observation is "important" without explaining why it is important. Doing so might help clarify their conclusions.

4\) In the subsection "Mutations in the active site of CYK-4 can be suppressed by RGA-3/4 depletion", the authors refer to hyper-contractility after RGA-3/4 depletion and imply (and to some extent document) that this phenotype is suppressed by CYK-4 mutants. The authors should more explicitly state if this is an accurate conclusion.

5\) In the subsection "Mutations in the active site of CYK-4 can be suppressed by RGA-3/4 depletion", the authors refer to an allelic series of CYK-4 mutants. It might be helpful to explicitly state why the different mutants exhibit this gradation in effect.

6\) In the first paragraph of the Discussion, the authors state that their data indicate that CYK-4 has to act catalytically on RhoA•GTP. The authors need to explain how their data support this conclusion.

7\) Is it possible that the suppressor mutations in ECT-2 (*xs110* and *xs111*) affect other functions than GEF activity? It might be worth discussing this possibility.

8\) In the subsection "Mechanism of ECT-2 activation and Positive Feedback", the authors refer first to [Figure 3](#fig3){ref-type="fig"}, and then to [Figures 2, 4, 5](#fig2 fig4 fig5){ref-type="fig"} as supporting two conclusions. It would help if the authors elaborate to explicitly state what data in these figures support these conclusions.

9\) The authors should explicitly state what they think the GAP active site does to influence ECT-2 GEF activity.

10\) In the subsection "Mechanism of ECT-2 activation and Positive Feedback", the authors state that CYK-4 GAP binds RhoA•GTP, but the model in [Figure 7E](#fig7){ref-type="fig"} in fact shows it binding RhoA:GDP. This should be explained.

11\) The model diagram ([Figure 7E](#fig7){ref-type="fig"}) did not really do much to help me understand how they authors think CYK-4 activates RhoA.

Reviewer \#3:

CYK-4 plays a crucial role in cytokinesis as a non-motor subunit of centralspindlin, which bundles microtubules to form the central spindle and midbody. However, the role of the RhoGAP domain of CYK-4 remains unclear or controversial as the authors nicely describe in the Introduction. The cell biological and genetical data that the Glotzer lab has been providing in a recent series of papers are indeed very difficult to explain with Rac or Cdc42 as sole targets of CYK-4 but are consistent with the positive role of CYK-4 on RhoA activation. A major difficulty of this theory is that a GAP usually promotes conversion of a GTPase from GTP-form to GDP-form, which is in general an inactive form, by stimulating the GTP hydrolysis. A clear molecular mechanism for CYK-4 to activate RhoA has been a huge missing link in the file of cytokinesis.

In this manuscript, the authors examined various mutations in the GAP domain of CYK-4 including the E448K mutation that had previously been identified as a temperature-sensitive lethal allele *(or749ts)* and can be suppressed by loss-of-function of the CED-10/Rac or its effectors. By combination with the loss-of-function of NOP-1, a mysterious activator of Ect2 RhoGEF specific for nematodes, and RGA-3/4, a well conserved GAP that specifically inactivates Rho, the authors have strengthen their previous conclusion "that the RhoGAP domain of CYK-4 has an essential role in RhoA activation" (this is the title of [@bib27]) except for a concern about the presence of other Rac proteins in addition to CED-10 (see below), which was not considered. Very interestingly, a screen for suppressors of *cyk-4(or749ts)* identified two novel alleles of Ect2 RhoGEF that cause its hyper activation, consistently with the proposed role of CYK-4 in RhoA activation. Finally, the authors tried to reveal biochemical mechanisms of RhoA activation by CYK-4 and found the direct binding between the GEF domain of ECT-2 and the C-terminal fragment of CYK-4 containing C1 and RhoGAP domains.

These are all interesting findings. However, it is questionable whether these are sufficient to support the authors' rather strong claim that the non-canonical activity of CYK-4 RhoGAP domain promotes RhoA activation though its interaction with the GEF domain of ECT-2. The novel interaction between CYK-4 GAP and ECT-2 GEF domains relies solely on a single binding experiment in [Figure 7B](#fig7){ref-type="fig"} (7C and 7D are just unconvincing attempts to explain the hyper activation of ECT-2 by the new *ect-2* alleles suggested by the in vivo phenotype). I really appreciate the amount of work necessary for the cell biology and genetics experiments. However, these are just strengthening their own already published claim. To propose a molecular mechanism of RhoA activation by the CYK-4 RhoGAP domain, stronger in vitro data should be provided at lease those obvious and feasible ones such as the influences of all the GAP mutations studied in vivo on the CYK-4-ECT-2 interaction.

Another concern is that the authors\' logics are sometimes inconsistent. For example, as the explanations for the similar weaker cortical accumulation of the E448K and EE mutants, which show very similar in vivo phenotypes (slow ingression and regression at ∼50% ingression around 300s, weaker cortical accumulation, no furrowing upon *nop-1* loss-of-function), they employed different reasonings, indirect effect on the function of C1 domain and the weakened interaction with RhoA, respectively. I agree with the authors on that mutations inside a protein fold might make the folding less stable more frequently than surface mutations and understand that a concern about this possibility prompted the current studies. However, this is an issue to be answered by proper biochemical/biophysical assays such as circular dichroism spectroscopy, which was undertaken in a recent paper from the Glotzer lab (White et al., 2013 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707682/>). Otherwise, based on the phenotypic similarity, it would be more reasonable to explain the phenotype of the E448K mutation is also caused by the reduced affinity to Rho (or other GTPases). Anyway, there are different possible mechanisms for the cortical recruitment of CYK-4 that are not necessarily exclusive to each other; C1-phosphoinositide interaction, GAP-Rho interaction, interaction with astral microtubule gathered by the ingressing furrow. This should be explained more explicitly rather than picking up a convenient one for individual cases.

Specific points:

1\) A table of the *C. elegans* strains used in this study with strain names and genotypes should be provided.

2\) The following statements are ambiguous: "The RhoGAP activity of CYK-4/MgcRacGAP functions non-canonically" (title), "serve as a RhoGAP" and "consistent with CYK-4 RhoGAP activity" (Abstract). It should be clarified what the authors mean by "RhoGAP". 'RhoGAP activity' could be any kind of activity that the RhoGAP domain has, the GAP activity against any Rho-family GTPase or a GAP activity specifically for Rho (but not for other GTPases such as Rac or Cdc42). It might be helpful to use "RhoGAP" for a domain name and "Rho-GAP", "Rac-GAP", "Rho-family-GAP" etc. for referring.

3\) In the subsection "RhoA activation during cytokinesis", the authors state: "The direct activator of RhoA during cytokinesis is the RhoGEF ECT-2". There are other RhoA activators during cytokinesis such as GEF-H1 (Birkenfeld J 2007 Dev. Cell <http://www.ncbi.nlm.nih.gov/pubmed/17488622>). "A major activator of RhoA..." would be reasonable.

4\) In the subsection "RhoA activation during cytokinesis", you claim that "recruitment of ECT-2 to the spindle midzone involves regulated binding between ECT-2 and CYK-4...". So far, the regulation of the interaction between CYK-4 and ECT-2 by phosphorylation by PLK-1 has only been shown in mammalian cells although there is no strong reason to imagine that the same regulation might not work in *C. elegans*.

5\) Please clarify the following reference: "...it appears to be required to activate RhoA (D\'Avino 2004)". Although D\'Avino et al. claimed "these observations are consistent with RacGAP50C inhibiting Rac and promoting Rho activity" and put RacGAP50C upstream to Rho in their model, this does not necessarily mean RacGAP50C is "required" for RhoA activation.

6\) "These results suggest that this mutation in CYK-4 affects more than the RhoGAP activity of CYK-4 or that CED-10/Rac1 is not the relevant target of the GAP domain, or both" (Introduction). This is neglecting another obvious possibility that there might be another Rac that works redundantly with CED-10. *C. elegans* has two additional Rac-related genes, RAC-2 and MIG-2.

7\) "...Subsequent analysis demonstrated that *cyk-4(or749ts)* does cause a phenotype in *ced-10*-embryos ([@bib27])" (Introduction). This might be due to elevated RAC-2 and MIG-2 activities by the *cyk-4* mutation, which still remained after the depletion of CED-10. Imperfect restoration of the wild-type behavior does not discredit the importance of the suppression of Rac and downstream effectors.

8\) [Figures 1A, 1B, 3A, 3B](#fig1 fig3){ref-type="fig"}: Why is there a big difference between the central spindle signal of CYK-4^∆C1^::GFP and CYK-4^E448K^::GFP? Five slices with 2.5 µm intervals should cover a range of 10 µm, which covers more than two thirds of the thickness of the 50%-ingressed cleavage furrow. For quantification, it is not clear how the usage of mCherry::PH as a standard is justified. The PH domain labels the plasma membrane by binding to phosphoinositides, which might be regulated by Rho-fmaily GTPases (<http://www.ncbi.nlm.nih.gov/pubmed/24914539>, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114633/>). Indeed, mCherry::PH signal at the 50%-ingresssed furrow is stronger in *cyk-4*^*R459A*^*::gap* embryo ([Figure 4B ii](#fig4){ref-type="fig"}) than in *cyk-4*^*WT*^ embryos ([Figure 1C](#fig1){ref-type="fig"} the first row, [Figure 4B i](#fig4){ref-type="fig"}). The intensities of mCherry::PH used for standardization must be presented.

9\) Another issue related to these experiments is that how CYK-4 accumulates at the furrow cortex is not clear. Although the authors mention it as accumulation on the plasma membrane, it might be reflecting the interactions between the C1 domain and phosphoinositides or between RhoGAP-Rho, or the compaction of the equatorial asters by the ingressing furrow.

10\) How about the temperature sensitivity of EE and R459A?

11\) In the subsection "The *cyk-4(or749ts)* allele, E448K, exhibits defects in membrane association", the authors state: "the onset of furrow ingression is delayed relative to controls in *cyk-4*^*E448K*^ embryos, but not in *cyk-4*^*∆C1*^ embryos". In [Figure 1C](#fig1){ref-type="fig"}, the deformation of the plasma membrane in the E448K embryo starts at the similar timing to the WT one (∼ at the 9th time point) while it becomes debatable in the ∆C1 embryo in the 11th or 12th time point. From the graph in [Figure 1F](#fig1){ref-type="fig"}, no clear difference is detected in the timing of the furrow initiation while the ingression is clearly slower in the E448K embryos.

12\) Please clarify the following passage: "...such that it facilitates the abscission step in *cyk-4(or749ts)*; *ced-10(n1933)* embryos". It is not clear why the abscission was suddenly mentioned while no experiment has been performed to specifically examine it.

13\) [Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}: Controls are missing to prove that the bands in the bead-bound fractions represent the specific binding to RhoA instead of beads or GST. Binding to the GST-alone beads needs to be performed in parallel. How is the binding affected by the E448K mutation?

14\) In the subsection "Mutants in the active site of the CYK-4 GAP domain are cytokinesis-defective", the authors claim: "Thus, the GAP activity of CYK-4 is not essential for post embryonic development but...". This is superficially true. However, there is another possibility that the mutant message/product might delay the consumption of the wild-type message/product derived from the heterozygous mother and kept the level of functional CYK-4 enough for post embryonic development (but not for maturation of germ line). The sentences "Thus, while early embryos require the GAP activity of CYK-4, this requirement is relaxed post embryonically" and "...as some cell types may not require the GAP activity of CYK-4, as seen in post embryonic cells in *C. elegans*" (subsection "GEF activation model accounts for previous results") should also be reconsidered.

15\) "CYK-4^R459A^ hyper accumulates on the membrane as compared to WT CYK-4; this localization suggests that CYK-4^R459A^ is well folded in vivo" -- is this logical? In general, partial misfolding might result in tighter membrane binding by forming small aggregates.

16\) The sentence: "If furrow formation is dependent on CYK-4 binding to either CED-10/Rac1 or CDC-42, then inactivation of these GTPases would be predicated to cause a phenotype at least as severe as a mutation that weakens the GTPase binding site of CYK-4". This inexplicitly assumes that these GTPases are positive regulators of the furrow formation. Thus, the logical conclusion of experimental observations is that furrow formation is independent of CYK-4 binding to them or that these are not positive regulators of the furrow formation.

17\) Figure 1--figure supplement 4 and 5: Is the structure on which CYK-4^E448K^::GFP was detected really the gonad membrane? The DIC image is not clear which structure is stained. Only after comparison with the images in Figure1--figure supplement 5 can readers understand what the structure labeled with the CYK-4 mutant in [Figure 1--figure supplement 4](#fig1s4){ref-type="fig"} is.

18\) Please clarify this statement: "These data demonstrate that the catalytic activity of the CYK-4 GAP domain must have a function that is distinct from maintaining CED-10/Rac1 in an inactive sate". This assumes that CED-10 is the only GTPase to be inactivated by CYK-4.

19\) "However, CYK-4 and ECT-2 form a protein complex through their regulatory N-termini, therefore the C-terminal RhoGAP domain of CYK-4 will be in the vicinity of the ECT-2 RhoGEF domain" (subsection "*cyk-4* suppressor mutations activate *ect-2*). This is not true. Whether the C-termini are in the vicinity is nothing to do with the fact that they bind through the N-termini.

20\) In the same subsection: "...the E129K substitution, but not G707D, significantly reduces binding of the ECT-2 N- and C-terminal ([Figure 7C](#fig7){ref-type="fig"})...". As the MBP-ECT-2_N wild type and E129K proteins are the different protein samples prepared independently, strictly, the data provided can\'t exclude a possibility that MBP-ECT-2_N wild-type shows stronger non-specific binding to the GSH-beads or GST than the E129K mutant. Control experiments with GST instead of GST-ECT-2_DHPH should be performed in parallel.

21\) In the Results: "The ECT-2G707D variant exhibits a modest increase in GEF activity compared to wild-type ECT-2 over a range of concentrations ([Figure 7D](#fig7){ref-type="fig"})." This is not really convincing. The same amount of the wild-type and mutant proteins are supposed to have been loaded on the gel. However, there is a small but clear difference in the intensity of the bands, especially the ∼50 kDa minor ones. I am afraid that there might also be a similar difference between the main bands. The difference between 1 µg and 1.2 µg is barely detectable by SDS-PAGE and Coomassie staining. In general, it is not trivial to quantify protein concentration with the precision of less than 10% error. Anyway, in the first place, it is questionable whether such a minor difference in the GEF activity can explain the dramatic in vivo phenotype.

22\) The references in this sentence are misleading: "Accurate reconstitutions will need to account for the facts that cytokinetic RhoA activation involves the CYK-4 C1 domain, the ability of CYK-4 to bind to ZEN-4, and the ability of ZEN-4 to oligomerize ([Figure 1C](#fig1){ref-type="fig"}) ([@bib1])." [Figure 1C](#fig1){ref-type="fig"} does not test the oligomerization. Defect in the oligomerization does not prevent RhoA activation (Hutterer, 2010 <http://www.ncbi.nlm.nih.gov/pubmed/19962307>, Dr. Glotzer is one of the authors of this paper). [@bib1] demonstrated elevated plasma membrane association of the centralspindlin mutant defective for 14-3-3-binding and thus promoted for oligomerization (*zen-4(S682A)*). However, it is not clear whether the rather global cortical contractility caused by this mutation is due to activation/inactivation of RhoA or other GTPases.

23\) "RhoA inactivation ([@bib28])" (subsection "GEF activation model accounts for previous results") -- this is misleading, as the major claim of this paper is the importance of the flux of RhoA turnover facilitated by combination of GEF and GAP for the formation of a sharp zone of the active form of RhoA.

24\) Legend for [Figure 6--figure supplement 1](#fig6s1){ref-type="fig"}: What was the temperature?

25\) In the subsection "Image quantification", it is not clear how the time-series data sets of the normalized cortical distance were analyzed by the Kruskal-Wallis test. Were the rates of ingression calculated and then tested? Or does the test directly compare the shape of the curves? Please provide details and proper references. Referring to the Kruskal-Wallis test by "ANOVA" (legends for [Figure 1F-I, 2C, 3D, 4C](#fig2 fig3 fig4 fig1){ref-type="fig"}) is confusing since ANOVA is usually used to refer to (parametric) analysis of variance, which requires the normality of the data, and different from the Kruskal-Wallis test, which is based on ranks and does not make any assumption about the probability distributions of the variables.

26\) [Figure 1B](#fig1){ref-type="fig"}, [Figure 1--figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 2D](#fig2){ref-type="fig"} and [Figure 3B](#fig3){ref-type="fig"}: For the *t*-tests, which method of correction for multiple comparison was used?

10.7554/eLife.08898.031

Author response

Reviewer \#1:

*\[...\] I think the paper is appropriate for publication in* eLife*. However, I would like to see the biochemistry developed better. In particular, I am surprised that none of the GAP mutants identified in the work have been characterized in the biochemical studies described in the latter part of the paper. The two key experiments are: 1) how do the GAP mutants behave in the physical interaction experiments with ECT2 and 2) how does the presence of wild-type or GAP mutants of CYK-4 affects the ECT2-mediated nucleotide exchange on RhoA. These experiments are crucial if they are to advance the model in* [*Figure 7*](#fig7){ref-type="fig"}*.*

We have assayed the binding of the GAP mutants binding to ECT--2. These data are included in [Figure 7--figure supplement 1](#fig7s1){ref-type="fig"} which demonstrates that the mutations do not affect the binding of CYK--4 GAP domain to the DH-PH domain of ECT--2.

I think some more discussion is also warranted on how mutations in the PH domain potentially affect the GEF activity. Molecular dynamics may help, although I realize this can be a new foray altogether.

The end of the Results section was amended by adding a concluding explanatory phrase: "The ECT--2G707D variant exhibits a modest increase in GEF activity compared to wild-type ECT--2 over a range of concentrations ([Figure 7D](#fig7){ref-type="fig"}), perhaps by increasing the affinity of ECT--2 for RhoA."

Reviewer \#2:

*\[...\] While the manuscript in my opinion clearly warrants publication in* eLife*, the authors first need to address the following concerns that, while perhaps relatively minor, nevertheless could possibly improve the clarity of their arguments.*

1\) In the Introduction, subsection "The role of the GAP activity of CYK-4 GAP has been controversial", the authors point out that CYK-4 has GAP activity toward RhoA but much more toward Rac1 and CDC-42. The authors should directly address how these observations relate to their conclusions concerning their model for how CYK-4 functions as an activator of RhoA.

We have more extensively addressed the differential activity of CYK--4 GAP activity towards Rho family GTPases in the Discussion. We suggest that it may be inactive towards RhoA because it would induce futile cycling of RhoA. We now mention that the activity toward Rac activity could have other functions in other contexts: "Not only does this model explain why CYK--4 retains GAP activity towards RhoA, it also explains why its ability to inactivate RhoA is attenuated. High turnover rates of RhoA•GTP induced by CYK--4 might rapidly consume RhoA•GTP at the site of production, yielding a futile cycle of RhoA activation and inactivation."

We have also added the statement (subsection "GEF activation model can account for many previous results"): "We do not rule out the possibility that, in certain contexts, CYK--4 or its orthologs negatively regulate Rac or Cdc42. Indeed, recent evidence indicates that the Xenopus ortholog of CYK--4 regulates junctional GTPases."

*2) With respect to* [*Figure 1*](#fig1){ref-type="fig"}*, the authors should discuss why there is some furrow ingression in embryos expressing CYK-4 lacking the C1 domain, and lacking* nop-1 *and* ced-10 *(in contrast to CYK-4*^*E448K*^*).*

In embryos expressing CYK--4^∆C1^ ([Figure 1D](#fig1){ref-type="fig"}) we observe some furrowing which is due to the presence of NOP--1 as it is absent in the double mutant ([Figure 1E](#fig1){ref-type="fig"}). The furrowing in *CYK--4*^*∆C1*^ embryos is slightly enhanced when CED--10 is mutated, however these embryos are not defective for NOP--1. We did not present data on CYK--4^∆C1^, *nop--1(-)* or *ced--10(-)*.

*3) In two places (subsection "The* cyk-4(or749ts) *allele, E448K, exhibits defects in membrane association" and "CYK-4 GAP domain mutations that prevent RhoA binding are highly defective in RhoA activation"), the authors conclude results paragraphs by stating that an observation is "important" without explaining why it is important. Doing so might help clarify their conclusions.*

We thank the reviewer for helping to clarify the manuscript. In the first case is it important because it shows that suppression of CYK--4 ^E448K^ by inactivation of *ced--10(-)* is completely dependent on NOP--1. That is, *nop--1(-)* and CYK--4^WT^ embryos are cytokinesis competent (and viable), but *nop--1(-)*, CYK--4^E448K^ and *ced--10(-)* are completely defective in furrowing which would not be the prediction if the sole function of the GAP activity of CYK--4 is to maintain CED--10 in the inactive state.

The revised text now reads: "Importantly, when NOP--1 activity is compromised, inactivation of CED--10/Rac1 does not suppress the defect in furrow ingression caused by CYK--4^E448K^ ([Figure 1J, I](#fig1){ref-type="fig"}), suggesting that CYK--4 does not act directly on CED--10."

Similarly in the second case, the result shows that whereas CYK--4^WT^ is capable of inducing furrow ingression in the absence of NOP--1 CYK--4EE is not. The revised text now reads: "Thus, Rho GTPase binding by CYK--4 is essential for centralspindlin-mediated cytokinetic ingression."

4\) In the subsection "Mutations in the active site of CYK-4 can be suppressed by RGA-3/4 depletion", the authors refer to hyper-contractility after RGA-3/4 depletion and imply (and to some extent document) that this phenotype is suppressed by CYK-4 mutants. The authors should more explicitly state if this is an accurate conclusion.

We did not intend to imply that all of the hypercontractility observed in RGA--3/4-depleted embryos is CYK--4 dependent. Indeed, in a previous publication we showed that the hypercontractility *during pseudocleavage* in RGA--3/4-depleted embryos is NOP--1 dependent. Thus RGA--3/4 depletion enhances RhoA activity, irrespective of the activator -- which in pseudocleavage is NOP--1 and in cytokinesis is primarily CYK--4. We modified this sentence to clarify this point without getting into too much detail: "As previously shown, depletion of RGA--3/4 causes cortical hypercontractility in otherwise wild-type embryos, *during both pseudocleavage and during cytokinesis*, and results in embryonic lethality ([Figure 5A](#fig5){ref-type="fig"}) ([@bib32]; [@bib33])". In addition, we added this to the Discussion: "However, loss of CYK--4 GAP activity and loss of RGA--3/4 counterbalance each other *during cytokinesis*".

5\) In the subsection "Mutations in the active site of CYK-4 can be suppressed by RGA-3/4 depletion", the authors refer to an allelic series of CYK-4 mutants. It might be helpful to explicitly state why the different mutants exhibit this gradation in effect.

6\) In the first paragraph of the Discussion, the authors state that their data indicate that CYK-4 has to act catalytically on RhoA•GTP. The authors need to explain how their data support this conclusion.

These are two excellent suggestions, which we have addressed by adding a supplemental figure ([Figure 7--figure supplement 2A](#fig7s2){ref-type="fig"}) and by adding a paragraph to the Discussion ("This working model is supported by the finding that full activation \[...\] within the ECT-- 2 GEF domain").

*7) Is it possible that the suppressor mutations in ECT-2 (*xs110 *and* xs111*) affect other functions than GEF activity? It might be worth discussing this possibility.*

Two lines of evidence indicate that these mutations increase the overall activity of ECT--2. First, the mutations cause an increase in contractility. Second, biochemical evidence indicates that *xs111* impairs the auto inhibitory binding between the N-and C-termini of ECT--2 and that *xs110* causes a modest increase in GEF activity. While circumstantial this interpretation is consistent with the partial suppression caused by depletion of RGA--3/4.

*8) In the subsection "Mechanism of ECT-2 activation and Positive Feedback", the authors refer first to* [*Figure 3*](#fig3){ref-type="fig"}*, and then to* [*Figures 2, 4, 5*](#fig2 fig4 fig5){ref-type="fig"} *as supporting two conclusions. It would help if the authors elaborate to explicitly state what data in these figures support these conclusions.*

Please see points 5 and 6 above.

9\) The authors should explicitly state what they think the GAP active site does to influence ECT-2 GEF activity.

Please see points 5 and 6 above.

*10) In the subsection "Mechanism of ECT-2 activation and Positive Feedback", the authors state that CYK-4 GAP binds RhoA•GTP, but the model in* [*Figure 7E*](#fig7){ref-type="fig"} *in fact shows it binding RhoA:GDP. This should be explained.*

Please see points 5 and 6 above.

*11) The model diagram (*[*Figure 7E*](#fig7){ref-type="fig"}*) did not really do much to help me understand how they authors think CYK-4 activates RhoA.*

We hope the additional paragraph and supplemental figure make our model more explicit and clarify this point (please see points 5 and 6, above).

Reviewer \#3:

Specific points:

*1) A table of the* C. elegans *strains used in this study with strain names and genotypes should be provided.*

Our strain table has been provided.

2\) The following statements are ambiguous: "The RhoGAP activity of CYK-4/MgcRacGAP functions non-canonically" (title), "serve as a RhoGAP" and "consistent with CYK-4 RhoGAP activity" (Abstract). It should be clarified what the authors mean by "RhoGAP". 'RhoGAP activity' could be any kind of activity that the RhoGAP domain has, the GAP activity against any Rho-family GTPase or a GAP activity specifically for Rho (but not for other GTPases such as Rac or Cdc42). It might be helpful to use "RhoGAP" for a domain name and "Rho-GAP", "Rac-GAP", "Rho-family-GAP" etc. for referring.

We have clarified the substrate for the RhoGAP activity in the Abstract. In addition, where possible, we have used the agnostic term GAP domain in many places and where we discuss RGA--3/4, we refer to it as a RhoA GAP.

*3) In the subsection "RhoA activation during cytokinesis", the authors state: "The direct activator of RhoA during cytokinesis is the RhoGEF ECT-2". There are other RhoA activators during cytokinesis such as GEF-H1 (Birkenfeld J 2007 Dev. Cell* [*http://www.ncbi.nlm.nih.gov/pubmed/17488622*](http://www.ncbi.nlm.nih.gov/pubmed/17488622)*). "A major activator of RhoA..." would be reasonable.*

ECT--2 is required for all RhoGAP activity during cytokinesis in human cells and *C. elegans*. We have revised this sentence to read: "The primary direct activator of RhoA during cytokinesis is the RhoGEF ECT--2".

*4) In the subsection "RhoA activation during cytokinesis", you claim that "recruitment of ECT-2 to the spindle midzone involves regulated binding between ECT-2 and CYK-4...". So far, the regulation of the interaction between CYK-4 and ECT-2 by phosphorylation by PLK-1 has only been shown in mammalian cells although there is no strong reason to imagine that the same regulation might not work in* C. elegans*.*

The reviewer is correct about this point. We do not wish to imply that this has been established for the *C. elegans* proteins, though, like the reviewer, we have no reason to believe that it is not the case for the following reasons. First, preliminary experiments suggested that Plk1 phosphorylation of *C. elegans* CYK--4 facilitates binding by *C. elegans* ECT--2. Secondly, Plk--1 depletion has been shown to impair completion of cytokinesis (PMID 20823068). Finally, in the sentences that precede this remark, we state: "Though these proteins are conserved, their names are distinct in each organism. For simplicity, *C. elegans* names will be used throughout this manuscript with the exception that we will refer to RHO--1 with the more common name RhoA." Thus, it is explicit that the statement in question does not necessarily refer to the nematode proteins and, indeed, the cited references refer to experiments in cultured mammalian cells.

*5) Please clarify the following reference: "...it appears to be required to activate RhoA (*[@bib10]*)". Although D\'Avino et al. claimed "these observations are consistent with RacGAP50C inhibiting Rac and promoting Rho activity" and put RacGAP50C upstream to Rho in their model, this does not necessarily mean RacGAP50C is "required" for RhoA activation.*

We have edited this phrase to "it appears to promote RhoA activation". In addition, the previous sentence also cites [@bib10] and states: "in others it appears to be important to negatively regulate Rac1".

*6) "These results suggest that this mutation in CYK-4 affects more than the RhoGAP activity of CYK-4 or that CED-10/Rac1 is not the relevant target of the GAP domain, or both" (Introduction). This is neglecting another obvious possibility that there might be another Rac that works redundantly with CED-10.* C. elegans *has two additional Rac-related genes, RAC-2 and MIG-2.*

We thank the reviewer for raising this point. We have addressed this point by a number of avenues. First, in the literature, [@bib7], reported:

"RNAi of CDC--42 or MIG--2 also did not ameliorate the CYK--4GAP(E448K) cytokinesis phenotype ([Figure 3D](#fig3){ref-type="fig"}). However, RNAi of CED--10 or RAC--2 led to substantial rescue, allowing 70% and 24%, respectively, of CYK--4GAP(E448K) embryos to successfully complete the first cytokinesis. Simultaneous RNAi of CED--10 and RAC--2 did not increase the efficiency of rescue over RNAi of RacCED--10 alone (Figure Supplement 4D)."

Thus previous work does not support a cytokinetic role for RAC--2 or MIG--2. However, as the authors noted in the supplemental information, the conservation between CED--10 and RAC--2 at the nucleotide level are such that either of these dsRNAs could, in principle, deplete both CED--10 and RAC--2.

To clarify this issue, several years ago, we examined whether a strong loss of function mutation in *ced--10* could suppress the cytokinetic defect in *cyk--4(or749ts)* and found that it could ([@bib27]). This strongly suggested that CED--10 is the major Rac protein whose activity modulates cytokinesis. If RAC--2 had a significant role, mutation of *ced--10* would not be predicted to phenocopy the potential co-depletion of both CED--10 and RAC--2. Furthermore, mutation of *ced--10* and depletion of the *arp2/3* subunit ARX--2 identically modified the phenotype *cyk--4(or749ts)* ([@bib27]). If both CED--10 and RAC--2 functioned upstream of *arx--2*, mutation of *ced--10* would be predicted to be less effective than depletion of ARX--2.

To further examine whether other Rac proteins will modulate cytokinesis in the early embryo, we depleted either ARX--2 or RAC--2 in *cyk--4*^*R459A*^ embryos. We found that depletion of ARX--2, but not RAC--2, rescued cytokinesis defect ([Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}). This suggests that RAC--2 is not a target for the GAP domain of CYK--4.

Furthermore, *mig-2* gain of function alleles (mutations in the equivalent of G12 of Ras) are viable, though they exhibit cell migration defects ([@bib52]). These gain of function phenotypes are significantly stronger than the corresponding null mutation. This indicates that the *mig--2* alleles are indeed activated alleles and the high viability of these strains suggests that *mig--2* does not regulate cytokinesis. To further investigate the possibility that *mig--2* does affect cytokinesis, we obtained a gain of function allele *mig--2(gm103)* and tested whether this allele affects cytokinesis in NOP--1 or ZYG--9 depleted embryos ([Figure 4--figure supplement 3](#fig4s3){ref-type="fig"}). These two depletions were chosen because they are effective ways of sensitizing cytokinesis to genetic perturbations (see PMID 17669650, 22918944 for examples). Unlike *cyk--4*^*R459A*^ embryos, *mig-- 2*;*nop--1* embryos successfully finish cytokinesis, indicating that activation of MIG--2 does not affect the centralspindlin-dependent pathway for furrow formation. In addition, *mig--2*;*zyg--9* embryos form both anterior and posterior furrows, indicating that the central spindle-independent and central spindle-dependent pathways are not affected by activation of MIG--2.

Next, we depleted either ARX--2 or RAC--2 from *nop--1;ced--10 cyk--4(or749ts)* embryos. We found that neither arx--2 nor rac--2 depletion modified the cytokinesis phenotypes in *nop--1;ced--10;cyk--4(or749ts)* embryos, i.e. *arx--2 nop--1;ced--10 cyk-- 4(or749ts)* and *rac--2;nop--1;ced--10 cyk--4(or749ts)* embryos had no furrow ingression during cytokinesis ([Figure 4--figure supplement 2](#fig4s2){ref-type="fig"}). These results suggest that RAC--2, nor any other proteins upstream of ARX--2, are critical targets for the GAP activity of CYK--4.

We note that previous studies have also concluded that: "by contrast, *ced--10* is uniquely required for cell-corpse phagocytosis, and *mig--2* and *rac--2* have only subtle roles in this process. (PMID 11714673)".

Thus, there are precedents for different Rac proteins in *C. elegans* functioning both redundantly and non-redundantly.

*7) "...Subsequent analysis demonstrated that* cyk-4(or749ts) *does cause a phenotype in* ced-10*-embryos (*[@bib27]*)" (Introduction). This might be due to elevated RAC-2 and MIG-2 activities by the* cyk-4 *mutation, which still remained after the depletion of CED-10. Imperfect restoration of the wild-type behaviour does not discredit the importance of the suppression of Rac and downstream effectors.*

Please see point 6.

*8)* [*Figures 1A, 1B, 3A, 3B*](#fig1 fig3){ref-type="fig"}*: Why is there a big difference between the central spindle signal of CYK-4*^*∆C1*^*::GFP and CYK-4*^*E448K*^*::GFP? Five slices with 2.5 µm intervals should cover a range of 10 µm, which covers more than two thirds of the thickness of the 50%-ingressed cleavage furrow. For quantification, it is not clear how the usage of mCherry::PH as a standard is justified. The PH domain labels the plasma membrane by binding to phosphoinositides, which might be regulated by Rho-fmaily GTPases (*[*http://www.ncbi.nlm.nih.gov/pubmed/24914539*](http://www.ncbi.nlm.nih.gov/pubmed/24914539)*,* [*http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114633/*](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114633/)*). Indeed, mCherry::PH signal at the 50%-ingresssed furrow is stronger in* cyk-4^R459A^::gap *embryo (*[*Figure 4B*](#fig4){ref-type="fig"} *ii) than* in cyk-4^WT^ *embryos (*[*Figure 1C*](#fig1){ref-type="fig"} *the first row,* [*Figure 4B i*](#fig4){ref-type="fig"}*). The intensities of mCherry::PH used for standardization must be presented.*

*E448K* is a Ts allele that retains central spindle assembly function, but it is not surprising that this temperature-sensitive mutation may not accumulate with wild-type efficiency at the restrictive temperature.

9\) Another issue related to these experiments is that how CYK-4 accumulates at the furrow cortex is not clear. Although the authors mention it as accumulation on the plasma membrane, it might be reflecting the interactions between the C1 domain and phosphoinositides or between RhoGAP-Rho, or the compaction of the equatorial asters by the ingressing furrow.

We agree with the reviewer's assessment that the exact mechanism by which CYK--4 accumulates at the furrow cortex is not entirely clear. However, the results in this manuscript suggest that membrane association of CYK--4 involves both its C1 domain and its ability to bind RhoA. In addition, our results indicate that it is not mediated by the compaction of the astral microtubules because its membrane localization domain is required, which would not be predicted to (nor are they seen to) affect central spindle assembly.

10\) How about the temperature sensitivity of EE and R459A?

CYK--4^EE^ and CYK--4^R459A^ fail to support viability at both 16°C and 25°C ([Figure 3--figure supplement 1B](#fig3s1){ref-type="fig"}).

*11) In the subsection "The* cyk-4(or749ts) *allele, E448K, exhibits defects in membrane association", the authors state: "the onset of furrow ingression is delayed relative to controls in* cyk-4^E448K^ *embryos, but not in* cyk-4^∆C1^ *embryos". In* [*Figure 1C*](#fig1){ref-type="fig"}*, the deformation of the plasma membrane in the E448K embryo starts at the similar timing to the WT one (∼ at the 9th time point) while it becomes debatable in the ∆C1 embryo in the 11th or 12th time point. From the graph in* [*Figure 1F*](#fig1){ref-type="fig"}*, no clear difference is detected in the timing of the furrow initiation while the ingression is clearly slower in the E448K embryos.*

The initial furrowing the reviewer is referring to in the case of *E448K* is so slight that it does not show up in the graphs. We have added the work "significant" prior to furrow ingression.

*12) Please clarify the following passage: "...such that it facilitates the abscission step in* cyk-4(or749ts); ced-10(n1933) *embryos". It is not clear why the abscission was suddenly mentioned while no experiment has been performed to specifically examine it.*

Abscission is mentioned because of the evidence from the Petronczki lab on the function of the C1 domain in human cells. If the defect in ∆C1 was very similar to that of *cyk--4(or749) \[E448K\]* then both mutants should be suppressed by ced--10 mutation, but suppression is only seen with *cyk--4(or749).* The sentence in question has been modified.

*13)* [*Figure 2--figure supplement 1*](#fig2s1){ref-type="fig"}*: Controls are missing to prove that the bands in the bead-bound fractions represent the specific binding to RhoA instead of beads or GST. Binding to the GST-alone beads needs to be performed in parallel. How is the binding affected by the E448K mutation?*

We have repeated these experiments to provide the requested controls ([Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}). However, as these additional controls render the figure significantly more complicated, we have not replaced the supplemental figure (though it would be straightforward to do if the editor/reviewers deemed it appropriate). The EE mutant serves as an internal control for CYK--4 GAP domains non-specifically binding to GST. We have not investigated the binding to RhoA by *E448K* allele because (i) this allele is not a primary focus of the manuscript, it only features in the manuscript to show that it is not an appropriate allele for specifically assessing GAP function and as an tool to obtain suppressor alleles; (ii) as a Ts allele, its behavior is expected to be temperature dependent and it is not uncommon for Ts alleles to exhibit more severe defect in vitro.

*14) In the subsection "Mutants in the active site of the CYK-4 GAP domain are cytokinesis-defective", the authors claim: "Thus, the GAP activity of CYK-4 is not essential for post embryonic development but...". This is superficially true. However, there is another possibility that the mutant message/product might delay the consumption of the wild-type message/product derived from the heterozygous mother and kept the level of functional CYK-4 enough for post embryonic development (but not for maturation of germ line). The sentences "...while early embryos require the GAP activity of CYK-4, this requirement is relaxed post embryonically" and "...as some cell types may not require the GAP activity of CYK-4, as seen in post embryonic cells in* C. elegans*" (subsection "GEF activation model accounts for previous results") should also be reconsidered.*

While it is formally possible that zygotic rescue is due to the indirect mechanism the review alludes to, however, we think this is very unlikely as equivalent zygotic rescue is not observed with CYK--4^∆C1^ which would be predicted to rescue via similar indirect effects.

*15) "CYK-4*^*R459A*^ *hyper accumulates on the membrane as compared to WT CYK-4; this localization suggests that CYK-4*^*R459A*^ *is well folded in vivo" -- is this logical? In general, partial misfolding might result in tighter membrane binding by forming small aggregates.*

As R459 is a charged residue on the surface of the protein, there is no reason a priori why it would cause misfolding. Furthermore, a misfolded protein would not be predicted to localize in a highly specific site in a cell cycle specific manner. Finally, this type of behavior has been observed previously with the RhoGAP RGA--3/4 (see [Figure 1H](#fig1){ref-type="fig"}, [@bib46] PMID 24012485).

16\) The sentence: "If furrow formation is dependent on CYK-4 binding to either CED-10/Rac1 or CDC-42, then inactivation of these GTPases would be predicated to cause a phenotype at least as severe as a mutation that weakens the GTPase binding site of CYK-4". This inexplicitly assumes that these GTPases are positive regulators of the furrow formation. Thus, the logical conclusion of experimental observations is that furrow formation is independent of CYK-4 binding to them or that these are not positive regulators of the furrow formation.

The reviewer is correct that this is an implicit assumption of the experiment. To address this concern, we have made this assumption explicit: "If furrow formation is dependent on CYK--4 binding to either CED--10/Rac1 or CDC--42 to generate a positive regulatory complex, then inactivation of these GTPases would be predicted to cause a phenotype at least as severe as a mutation that weakens the GTPase binding site of CYK--4."

*17) Figure 1--figure supplement 4 and 5: Is the structure on which CYK-4*^*E448K*^*::GFP was detected really the gonad membrane? The DIC image is not clear which structure is stained. Only after comparison with the images in Figure1--figure supplement 5 can readers understand what the structure labeled with the CYK-4 mutant in Figure 1--figure supplement 4 is.*

To clarify this point, we have merged Figure 1--figure supplements 4 and 5.

18\) Please clarify this statement: "These data demonstrate that the catalytic activity of the CYK-4 GAP domain must have a function that is distinct from maintaining CED-10/Rac1 in an inactive sate". This assumes that CED-10 is the only GTPase to be inactivated by CYK-4.

See point 6 above.

*19) "However, CYK-4 and ECT-2 form a protein complex through their regulatory N-termini, therefore the C-terminal RhoGAP domain of CYK-4 will be in the vicinity of the ECT-2 RhoGEF domain" (subsection "*cyk-4 *suppressor mutations activate* ect-2*). This is not true. Whether the C-termini are in the vicinity is nothing to do with the fact that they bind through the N-termini.*

The issue here appears to be a semantic one related to the definition of vicinity. When two proteins form a complex, they are in the vicinity of each other (i.e. within ∼ 10 nm, depending on the size/shape of the proteins). Assuming the various domains are connected by flexible linkers, the interaction of one domain on each of the two proteins would greatly favor the interaction with the other, by virtue of increasing their effective concentration. This is described in detail in an excellent review by Kuriyan and Eisenberg (PMID 18075577).

*20) In the same subsection: "...the E129K substitution, but not G707D, significantly reduces binding of the ECT-2 N- and C-terminal (*[*Figure 7C*](#fig7){ref-type="fig"}*)...". As the MBP-ECT-2_N wild type and E129K proteins are the different protein samples prepared independently, strictly, the data provided can\'t exclude a possibility that MBP-ECT-2_N wild-type shows stronger non-specific binding to the GSH-beads or GST than the E129K mutant. Control experiments with GST instead of GST-ECT-2_DHPH should be performed in parallel.*

We have performed this additional control experiment which demonstrated that the interaction is not mediated via the GST domain ([Figure 7--figure supplement 1B](#fig7s1){ref-type="fig"}). Again, we leave the original simpler figure as the E129K mutant provides and internal control that MBP-ECT--2N constructs do not non-specifically interact with GST tagged ECT--2C constructs.

*21) In the Results: "The ECT-2G707D variant exhibits a modest increase in GEF activity compared to wild-type ECT-2 over a range of concentrations (*[*Figure 7D*](#fig7){ref-type="fig"}*)". This is not really convincing. The same amount of the wild-type and mutant proteins are supposed to have been loaded on the gel. However, there is a small but clear difference in the intensity of the bands, especially the ∼50 kDa minor ones. I am afraid that there might also be a similar difference between the main bands. The difference between 1 µg and 1.2 µg is barely detectable by SDS-PAGE and Coomassie staining. In general, it is not trivial to quantify protein concentration with the precision of less than 10% error. Anyway, in the first place, it is questionable whether such a minor difference in the GEF activity can explain the dramatic in vivo phenotype.*

This mutation certainly provides rescue of both *cyk--4(or749)* and *cyk-4*^*R459A*^; structural homology modeling suggests this mutation lies near the Rho binding interface and a reproducible increase in specific activity is observed. The reviewer questions whether this change is specific activity is sufficient to explain the phenotype in vivo. Given the available information, the simplest interpretation is that the mutation increase GEF activity. It is possible that the in vivo assay in dilute aqueous solutions doesn't fully capture the effect that this mutation has in vivo.

*22) The references in this sentence are misleading: "Accurate reconstitutions will need to account for the facts that cytokinetic RhoA activation involves the CYK-4 C1 domain, the ability of CYK-4 to bind to ZEN-4, and the ability of ZEN-4 to oligomerize (*[*Figure 1C*](#fig1){ref-type="fig"}*) (*[@bib1]*)."* [*Figure 1C*](#fig1){ref-type="fig"} *does not test the oligomerization. Defect in the oligomerization does not prevent RhoA activation (Hutterer, 2010* [*http://www.ncbi.nlm.nih.gov/pubmed/19962307*](http://www.ncbi.nlm.nih.gov/pubmed/19962307)*, Dr. Glotzer is one of the authors of this paper).* [@bib1] *demonstrated elevated plasma membrane association of the centralspindlin mutant defective for 14-3-3-binding and thus promoted for oligomerization (zen-4(S682A)). However, it is not clear whether the rather global cortical contractility caused by this mutation is due to activation/inactivation of RhoA or other GTPases.*

The citations were collected at the end of the sentence for clarity. They have been relocated within the sentence to address this reviewer's concerns. Although the reviewer is correct that mutation in the oligomerization domain does not prevent furrowing, it is important to note that the defect in oligomerization motif was assayed in the presence of NOP--1, which we have shown is sufficient to induce furrowing in *cyk--4* mutant embryos. However, this point is addressed by Basant et al. In that paper we showed that *nop--1;air--2* embryos are defective in contractility and this defect can be completely reversed by depletion of par--5. Furthermore, the hypercontractility phenotype caused by depletion of PAR--5 is phenocopied by mutation of ZEN--4 S682A (which is unable to bind PAR--5). PAR--5 was previously shown to inhibit centralspindlin oligomerization by binding to phospho-S682 MKLP1 (PMID 20451386). Collectively, these results indicate that the defect in RhoA activation in *nop--1; air--2* mutants is caused by a failure of centralspindlin to oligomerize. Furthermore, in Basant et al., we showed that the hypercontractility caused by PAR--5 depletion (which is phenocopied by mutation of ZEN--4 S682A ([Figure 6](#fig6){ref-type="fig"}) is ECT--2-dependent ([Figire 1 C, D](#fig1){ref-type="fig"}) and is associated with an increase in RhoA activation ([Figure 2A](#fig2){ref-type="fig"}). In summary, hyperoligomerization of ZEN--4 (either PAR--5 depletion or S682A) induces hyperactivation of RhoA and hypo-oligomerization of ZEN--4 (aurora B inhibition) prevents RhoA activation.

*23) "RhoA inactivation (*[@bib28]*)" (subsection "GEF activation model accounts for previous results") -- this is misleading, as the major claim of this paper is the importance of the flux of RhoA turnover facilitated by combination of GEF and GAP for the formation of a sharp zone of the active form of RhoA.*

While the authors of this paper interpret their results as indicating the importance of flux, they did not directly measure flux. They did demonstrate that inactivation of the GAP activity of CYK--4 results in an increase in RhoA activation. Indeed the Abstract of that paper states: "We propose that the GAP domain of MgcRacGAP has two unexpected roles throughout cytokinesis: first, it transiently anchors active Rho, and second, it promotes local Rho inactivation, resulting in the constant flux of Rho through the GTPase cycle".

24\) Legend for Figure 6--figure supplement 1: What was the temperature?

These experiments were performed at 25°C.

*25) In the subsection "Image quantification", it is not clear how the time-series data sets of the normalized cortical distance were analyzed by the Kruskal-Wallis test. Were the rates of ingression calculated and then tested? Or does the test directly compare the shape of the curves? Please provide details and proper references. Referring to the Kruskal-Wallis test by "ANOVA" (legends for* [*Figure 1F-I, 2C, 3D, 4C*](#fig2 fig3 fig4 fig1){ref-type="fig"}*) is confusing since ANOVA is usually used to refer to (parametric) analysis of variance, which requires the normality of the data, and different from the Kruskal-Wallis test, which is based on ranks and does not make any assumption about the probability distributions of the variables.*

We thank the reviewer for calling our attention to this issue. We have revised the manner in which we present the ingression rates. Rather than plotting the data with S.E.M., we instead provide 95% confidence intervals for each point. Thus, from inspection, the reader can directly observe that the data sets are distinct.

*26)* [*Figure 1B*](#fig1){ref-type="fig"}*,* [*Figure 1--figure supplement 2*](#fig1s2){ref-type="fig"}*,* [*Figure 2D*](#fig2){ref-type="fig"} *and* [*Figure 3B*](#fig3){ref-type="fig"}*: For the* t*-tests, which method of correction for multiple comparison was used?*

[Figure 1B](#fig1){ref-type="fig"}, [Figure1--figure supplement 2, and Figure 3B](#fig1s2 fig3){ref-type="fig"} were analyzed by one way ANOVA followed by Tukey multiple comparison. [Figure 1B](#fig1){ref-type="fig"}, [Figure 1--figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 2D](#fig2){ref-type="fig"}, has only two data sets, so it was analyzed by *t*-test.
